# HE 10 - Economic Evaluation II: Methodological Foundations for Robust Economic Evaluations  

**MQB7014: Health Economics**  
**Master of Public Health (MPH) Programme, University of Malaya**  
**Prepared by: Dr Ainol Haniza Kherul Anuwar**  
**DDS (UGM), MCOH (Distinction) (Malaya), DrDPH (Malaya)**  
**Department of Community Oral Health & Clinical Prevention, Faculty of Dentistry, Universiti Malaya**  
**Credit: Prof Dr Maznah Dahlui, Department of Social & Preventive Medicine, Faculty of Medicine, Universiti Malaya**  

---

## üìù Executive Summary

The lecture provides a comprehensive framework for conducting **robust economic evaluations** in Malaysia‚Äôs resource-constrained healthcare system üåç. Building on foundational concepts, the lecture focuses on the **methodological rigor**, **transparency**, and **policy relevance** required to evaluate **costs** and **outcomes** of healthcare interventions, such as cancer treatments or rural health programs. Through **10 key steps**, **case studies**, and a focus on avoiding common pitfalls, the lecture equips public health professionals to navigate **scarcity**, ensuring **efficiency**, **equity**, and **sustainability** in resource allocation ü©∫. Below is a summary of the main sections, key takeaways, and **terminologies** introduced, emphasizing their application in Malaysia‚Äôs context.

### üìö Overview of Economic Evaluation Methodologies

**Economic Evaluation II** shifts from theory to practice, outlining the **"how"** of conducting a **full economic evaluation**. It emphasizes **methodological clarity** and **transparency** to support **evidence-based decisions** in Malaysia, where **scarcity** drives the need for **efficient resource allocation**.

- **Learning Outcomes**:
    - **Outline** the 10 steps of a full economic evaluation üìã.
    - **Identify and measure** costs (e.g., drugs, travel) and outcomes (e.g., QALYs) üí∞üìà.
    - **Apply** concepts like **discounting**, **ICER**, and **sensitivity analysis** üßÆ.
    - **Understand** the role of **modeling** in simulating complex scenarios üìä.
- **Relevance**: In Malaysia, evaluations guide decisions on interventions like HPV vaccines, ensuring **maximum health impact** within limited budgets.

**Key Terminology**:

- **Full Economic Evaluation**: A systematic comparison of two or more interventions in terms of **costs** and **outcomes** to inform resource allocation (Drummond et al., 2005).

### ü©∫ Recap of Economic Evaluation Basics

This section revisits foundational concepts, grounding the practical steps in **economic principles** and **perspectives**.

- **Definition**: _Economic evaluation_ is a _comparative analysis of alternative courses of action in terms of both their costs and consequences_ (Drummond et al., 2005).
- **Types**:
    - **CMA (Cost-Minimization Analysis)**: Compares costs for equivalent outcomes.
    - **CEA (Cost-Effectiveness Analysis)**: Uses **natural units** (e.g., life-years gained).
    - **CUA (Cost-Utility Analysis)**: Employs **utility-based measures** (e.g., QALYs, DALYs).
    - **CBA (Cost-Benefit Analysis)**: Converts outcomes to **monetary terms** (RM).
- **Principles**:
    - **Scarcity**: Limited resources necessitate choices üìâ.
    - **Opportunity Cost**: Value of the next best alternative forgone üí∏.
    - **Efficiency**: Maximizing health outcomes per resource unit üåü.
    - **Marginal Analysis**: Evaluating incremental costs and effects üìà.
- **Perspective**: Defines which **costs** and **outcomes** are included (e.g., **societal**, **health system**, **payer**, **patient**), affecting conclusions ‚öñÔ∏è.
- **Relevance**: In Malaysia, these concepts ensure evaluations align with **policy goals**, such as improving **equity** in rural healthcare access.

**Key Terminology**:

- **Scarcity**: Limited availability of healthcare resources requiring prioritization.
- **Opportunity Cost**: The value of benefits lost by choosing one intervention over another.
- **Efficiency**: Achieving maximum health outcomes per unit of resource.
- **Marginal Analysis**: Assessing additional costs and benefits of scaling an intervention.
- **Perspective**: The viewpoint (e.g., societal, health system) determining which costs and outcomes are considered.

### üìã Steps in Conducting a Full Economic Evaluation

The lecture outlines **10 steps** for a **full economic evaluation**, ensuring **methodological rigor** and **policy relevance**:

1. **Define Problem and Comparators**: Specify the health issue and interventions (e.g., HPV vaccine for boys vs. girls) üíâ.
2. **Choose Perspective**: Select whose costs and benefits to include (e.g., health system for budget focus) üëÅÔ∏è.
3. **Set Time Horizon**: Determine duration for analysis (e.g., 5 years for dental clinics, lifetime for chronic diseases) ‚è∞.
4. **Identify, Measure, Value Costs**: Quantify resources like **direct medical** (drugs), **non-medical** (travel), **indirect** (productivity losses), and **intangible** (pain) costs üí∞.
5. **Identify and Measure Outcomes**: Select **natural units** (CEA), **QALYs/DALYs** (CUA), or **monetary values** (CBA) üìà.
6. **Apply Discounting**: Adjust future values using a **3‚Äì5% rate** (Malaysia: 3%) üï∞Ô∏è.
7. **Conduct Incremental Analysis**: Calculate **ICER** as $$\text{ICER} = \frac{\text{Cost}_{\text{New}} - \text{Cost}_{\text{Comparator}}}{\text{Effect}_{\text{New}} - \text{Effect}_{\text{Comparator}}}$$ üßÆ.
8. **Perform Sensitivity Analysis**: Test **robustness** under uncertainty üî¨.
9. **Use Modeling**: Simulate complex scenarios with **decision trees** or **Markov models** üìä.
10. **Interpret and Present Results**: Use **cost-effectiveness planes** or **league tables** to align with **policy priorities** üìú.

- **Case Example**: A **mobile dental clinic** vs. **subsidy scheme** in rural Malaysia illustrates these steps, assessing costs (e.g., van purchase) and outcomes (e.g., cavities treated) to calculate an ICER, guiding **equity-focused** decisions ü¶∑.
- **Relevance**: These steps ensure evaluations are **systematic** and **context-specific**, supporting Malaysia‚Äôs health system in prioritizing interventions like vaccinations or rural healthcare programs.

**Key Terminology**:

- **Incremental Cost-Effectiveness Ratio (ICER)**: Cost per additional unit of health benefit, calculated as $$\text{ICER} = \frac{\Delta \text{Cost}}{\Delta \text{Effect}}$$.
- **Time Horizon**: Duration of cost and outcome measurement.
- **Discounting**: Adjusting future costs and outcomes to present value using a discount rate (e.g., 3%).

### üí∞ Costing in Economic Evaluation

Costing is the **foundation** of economic evaluation, requiring **systematic identification**, **measurement**, and **valuation** of resources.

- **Definition**: _Cost_ is _the value of resources consumed to deliver an intervention or service_.
- **Types**:
    - **Direct Medical**: Health system costs (e.g., chemotherapy drugs) ü©∫.
    - **Direct Non-Medical**: Patient access costs (e.g., travel) üöó.
    - **Indirect**: Productivity losses (e.g., sick leave) üíº.
    - **Intangible**: Non-financial costs (e.g., pain) üòü.
- **Costing Process**:
    - **Identification**: List resources (e.g., chemo sessions).
    - **Measurement**: Quantify use (e.g., 6 cycles) using **patient records** or **databases**.
    - **Valuation**: Assign monetary values (e.g., RM 1,500 per cycle) using **tariffs** or **market prices**.
- **Micro-Costing vs. Gross-Costing**:
    - **Micro-Costing**: Detailed, precise, for clinical trials üìè.
    - **Gross-Costing**: Average costs, for budget planning üìà.
- **Example**: Costing **Drug A** (RM 5,000/cycle) vs. **Drug B** (RM 1,200/cycle) for breast cancer, including **side effect management** and **travel costs** (societal perspective).
- **Perspective Impact**: Costs vary by perspective, affecting **ICER** interpretation (e.g., societal finds Drug A **cost-effective** due to productivity gains, health system may not) ‚öñÔ∏è.
- **Relevance**: Accurate costing ensures **credible evaluations** in Malaysia, aligning with **budget constraints** and **equity goals**.

**Key Terminology**:

- **Cost**: Monetary value of resources consumed.
- **Micro-Costing**: Detailed itemization of resource costs.
- **Gross-Costing**: Use of average costs per service unit.

### üìä Measuring Outcomes

Outcomes quantify the **health benefits** of interventions, tailored to the evaluation type.

- **Definition**: _Outcomes_ are _the consequences of an intervention on health_.
- **Types**:
    - **Natural Units** (CEA): Life-years gained, cases detected ü©∫.
    - **Utility-Based** (CUA): **QALYs** (Quality-Adjusted Life Years), **DALYs** (Disability-Adjusted Life Years) üåü.
    - **Monetary** (CBA): RM value of productivity üí∏.
- **QALY**: Combines **length** and **quality of life** (0 = death, 1 = perfect health). Example: 1 year with side effects (utility = 0.6) = **0.6 QALYs**.
- **Utility Measurement**:
    - **EQ-5D**: Standardized health state tool üìã.
    - **Time Trade-Off (TTO)**: Time sacrificed for better health üï∞Ô∏è.
    - **Standard Gamble**: Risk accepted for full health üí°.
- **Example**: For breast cancer, **Drug A** yields more **QALYs** than **Drug B** due to fewer side effects, impacting **CUA** results.
- **Relevance**: In Malaysia, **QALYs** are key for **patient-centered** evaluations, ensuring **equity** in assessing interventions like cancer therapies.

**Key Terminology**:

- **Outcome**: Health impact of an intervention.
- **QALY (Quality-Adjusted Life Year)**: Measure combining life length and quality (0‚Äì1 scale).
- **DALY (Disability-Adjusted Life Year)**: Measure of disease burden, combining years lost and years lived with disability.
- **Utility**: Numerical value of health state quality (e.g., 0.6 for side effects).

### ‚è∞ Time-Related Considerations

Timing affects the **value** of costs and outcomes, requiring adjustments for **fair comparisons**.

- **Time Preference**: People value **benefits now** over later üï∞Ô∏è.
- **Discounting**: Adjusts future values to present using a **3‚Äì5% rate** (Malaysia: 3%). Example: 0.8 QALYs become ~0.76 QALYs at 3% discount.
- **Time Horizon**:
    - **Short-term** (‚â§1 year): For acute illnesses.
    - **Long-term** (10‚Äì20 years or lifetime): For chronic or preventive interventions.
    - **Risk**: Short horizons miss **long-term benefits** (e.g., breast cancer survival gains).
- **Relevance**: In Malaysia, **discounting** and **long-term horizons** ensure accurate evaluation of **preventive programs** like vaccinations, aligning with **sustainability** goals.

**Key Terminology**:

- **Time Preference**: Preference for immediate benefits over future ones.
- **Time Horizon**: Duration of cost and outcome measurement.

### üìà Incremental Analysis and ICER

**Incremental analysis** compares **additional costs** and **benefits**, using the **ICER** to assess **cost-effectiveness**.

- **Definition**: _Compares the additional cost and benefit of one intervention versus another_, asking _‚ÄúHow much more for each extra outcome?‚Äù_
- **ICER Formula**: $$\text{ICER} = \frac{\text{Cost}_{\text{New}} - \text{Cost}_{\text{Comparator}}}{\text{Effect}_{\text{New}} - \text{Effect}_{\text{Comparator}}}$$
- **Example**: For **HER2+ breast cancer**, Drug A (RM 60,000, 2.0 QALYs) vs. Drug B (RM 20,000, 1.5 QALYs) yields $$\text{ICER} = \frac{40,000}{0.5} = \text{RM 80,000 per QALY}$$.
- **Thresholds**:
    - **WTP**: RM 90,000‚Äì120,000/QALY (MOH/HTA).
    - **GDP**: ~RM 50,000/QALY (1√ó GDP, highly cost-effective); RM 50,000‚Äì150,000/QALY (1‚Äì3√ó GDP, cost-effective).
    - **Opportunity Cost**: RM 30,000‚Äì50,000/QALY (health gains forgone).
- **Cost-Effectiveness Plane**: Visualizes trade-offs (NE: more costly, more effective; SE: adopt; SW: trade-offs; NW: reject).
- **Mini Case**: Colorectal cancer drug (ICER = RM 80,000/QALY) is **cost-effective** at WTP (RM 100,000) but **not** at GDP or opportunity cost thresholds.
- **Relevance**: In Malaysia, ICER guides **budget allocation**, balancing **health gains** with **cost constraints**.

**Key Terminology**:

- **Cost-Effectiveness Plane**: Visual tool plotting incremental costs vs. effectiveness across four quadrants.

### üî¨ Sensitivity Analysis

**Sensitivity analysis** tests **robustness** under **uncertainty**, ensuring **reliable** results.

- **Purpose**: Tests how **results change** with uncertain parameters (e.g., costs, utilities).
- **Types**:
    - **One-Way**: Vary one parameter (e.g., Drug A cost from RM 60,000 to RM 40,000).
    - **Multi-Way**: Vary multiple parameters.
    - **Scenario Analysis**: Test real-world scenarios (e.g., public vs. private costs).
    - **Probabilistic (PSA)**: Use Monte Carlo simulations.
    - **Threshold Analysis**: Find value where results change (e.g., maximum drug price).
- **Tornado Diagram**: Visualizes **parameter impact** on costs, with wider bars indicating **greater influence**.
- **Example**: For breast cancer, lowering Drug A‚Äôs price to RM 45,000 reduces ICER to **RM 50,000/QALY** (cost-effective).
- **Relevance**: In Malaysia, sensitivity analysis ensures **confidence** in recommendations, addressing data variability in **rural** or **urban** settings üîç.

**Key Terminology**:

- **Sensitivity Analysis**: Testing result robustness under parameter uncertainty.
- **Tornado Diagram**: Visual ranking of parameter impacts on incremental costs.

### üßÆ Economic Modeling

**Economic modeling** simulates **complex** or **long-term** scenarios when data are limited.

- **Definition**: _Simplified representations of clinical and economic processes_.
- **Scenarios**:
    - Short-term trial data needing **long-term projection**.
    - Complex **care pathways** or **disease stages**.
    - **Rare diseases** or **budget forecasting**.
- **Types**:
    - **Decision Tree**: For short-term decisions (e.g., 6-month cancer treatment).
    - **Markov Model**: For chronic conditions, with **states** (e.g., well, recurrence), **cycles** (yearly), **transition probabilities**, and **utilities/costs**.
- **Example**: Breast cancer model projects **lifetime QALYs** and **costs** beyond 2-year trial data.
- **Advantages**: Captures **long-term outcomes**, **patient variability**, and supports **scenario analysis**.
- **Limitations**: Relies on **assumptions**, **data quality**, and requires **transparency**.
- **Relevance**: In Malaysia, modeling supports **long-term planning** for chronic diseases and preventive programs üìä.

**Key Terminology**:

- **Economic Model**: Simplified framework for simulating healthcare scenarios.
- **Decision Tree**: Model for short-term decisions with branches for choices and outcomes.
- **Markov Model**: Model for chronic conditions with health states and transitions.

### üìö Case Study: HER2+ Breast Cancer

This case applies the **10 steps** to compare **Drug A** (targeted therapy) vs. **Drug B** (standard chemotherapy).

- **Parameters**: **Health system perspective**, **5-year horizon**, **3% discount rate**.
- **Data**: Drug A (RM 60,000, 2.0 QALYs) vs. Drug B (RM 20,000, 1.5 QALYs).
- **Calculations**:
    - Incremental Cost: $$60,000 - 20,000 = \text{RM 40,000}$$
    - Incremental QALYs: $$2.0 - 1.5 = 0.5 \text{ QALYs}$$
    - ICER: $$\text{ICER} = \frac{40,000}{0.5} = \text{RM 80,000 per QALY}$$
- **Interpretation**:
    - **Cost-effective** at WTP (RM 100,000/QALY).
    - **Not cost-effective** at GDP (RM 50,000/QALY) or opportunity cost (RM 30,000‚Äì50,000/QALY).
    - **Decision Factors**: **Budget constraints**, **disease severity**, **equity** (access for low-income patients).
- **Relevance**: Demonstrates practical application in Malaysia, balancing **cost-effectiveness** with **equity** ü©∫.

### üö´ Common Mistakes in Economic Evaluation

Avoiding errors ensures **credibility** and **policy relevance**:

- **Inappropriate/Unstated Perspective**: Misaligns costs/outcomes (e.g., ignoring OOP costs).
- **Incorrect Costing**: Using outdated or inconsistent prices.
- **Inadequate Time Horizon**: Missing long-term benefits (e.g., 1-year horizon for cancer).
- **No Discounting**: Overstating future benefits.
- **Weak Sensitivity Analysis**: Ignoring uncertainty.
- **ICER Misuse**: Reporting total costs without comparison.
- **Lack of Transparency**: Unclear assumptions or methods.
- **Relevance**: In Malaysia, avoiding these ensures **trustworthy evaluations** for policy decisions üìë.

### ‚úÖ Conclusion

**Robust economic evaluations** demand **methodological clarity**, **transparency**, and **policy relevance**, systematically comparing **cost** and **value** to support **wise decisions**. They navigate **scarcity**, ensuring **efficiency**, **equity**, and **sustainability**, guiding Malaysia toward **better health outcomes** üá≤üáæ.

---

## üìö 1. Introduction to Economic Evaluation Methodologies

**Economic Evaluation II** builds on the foundational concepts introduced in **Economic Evaluation I**, diving deeper into the practical **"how"** of conducting a **full economic evaluation**. This lecture, delivered on **May 30, 2025**, provides a **systematic framework** for evaluating **costs** and **outcomes** of healthcare interventions, emphasizing **methodological rigor**, **transparency**, and **policy relevance**. It is particularly relevant for Malaysia‚Äôs health system, where **scarcity** drives the need for **efficient resource allocation** üåç. By mastering these methodologies, public health professionals can make informed decisions to optimize limited resources, ensuring better health outcomes for communities.

### üéØ Learning Outcomes

By the end of this session, students will be equipped with the skills to navigate the complexities of economic evaluations in healthcare. Specifically, they should be able to:

- **Outline** the key steps in conducting a **full economic evaluation**, ensuring a structured approach to comparing healthcare interventions üìã.
- **Identify** and **measure** relevant **costs** and **health outcomes**, accurately capturing the resources used and benefits gained üí∞üìà.
- **Apply** core concepts such as **discounting**, **Incremental Cost-Effectiveness Ratio (ICER)**, and **sensitivity analysis**, to assess the value of interventions with precision üßÆ.
- **Understand** the role of **modeling** in economic evaluation, using tools like decision trees and Markov models to simulate real-world scenarios üìä.

These outcomes empower students to contribute to **evidence-based decision-making**, particularly in resource-constrained settings like Malaysia‚Äôs public health system, where every ringgit spent must maximize health impact üåü.

### üìã Summary Table: Learning Outcomes

| **Outcome**             | **Description**                                                                   | **Why It Matters**                                                                       |
| ----------------------- | --------------------------------------------------------------------------------- | ---------------------------------------------------------------------------------------- |
| **Outline Steps**       | List and describe the key steps in a full economic evaluation                     | Ensures a systematic approach to comparing interventions, avoiding oversights üìã         |
| **Identify & Measure**  | Determine relevant costs (e.g., drugs, hospital stays) and outcomes (e.g., QALYs) | Provides accurate data for credible evaluations, reflecting true resource use üí∞         |
| **Apply Concepts**      | Use discounting, ICER, and sensitivity analysis                                   | Enables precise assessment of intervention value, accounting for time and uncertainty üßÆ |
| **Understand Modeling** | Recognize the role of decision trees and Markov models                            | Simulates complex scenarios, bridging data gaps for long-term decisions üìä               |

### üìñ Why This Matters

Economic evaluations are critical in healthcare because they provide a **structured way** to compare the **costs** and **benefits** of different interventions. In Malaysia, where **scarcity** of resources is a constant challenge, these evaluations help policymakers allocate budgets efficiently, ensuring that interventions deliver the **greatest health benefits** for the population. **Economic Evaluation II** shifts the focus from theoretical foundations (covered in Economic Evaluation I) to **practical application**, teaching students how to design, conduct, and interpret evaluations that are **methodologically sound**, **transparent**, and **relevant to policy needs**. This lecture equips students with the tools to address real-world questions, such as whether a new vaccine or treatment is worth the investment, making it a cornerstone of public health decision-making ü©∫.

---

## ü©∫ 2. Recap of Economic Evaluation Basics

This section revisits the **foundational concepts** of economic evaluation, setting the stage for the practical methodologies covered in **Economic Evaluation II** to ensure students grasp the **core principles**, **types**, and **perspectives** of economic evaluation, which are critical for making informed decisions in Malaysia‚Äôs resource-scarce healthcare system üåç. By understanding **what economic evaluation is**, **how it varies**, and **why perspective matters**, students can better appreciate the tools and steps needed to conduct robust evaluations that maximize health outcomes efficiently ü©∫.

### üìñ What is Economic Evaluation?

- **Definition**: _‚ÄúA comparative analysis of alternative courses of action in terms of both their costs and consequences.‚Äù_
    - **Source**: Drummond et al. (2005).
- **Core Idea**: Economic evaluation helps decision-makers allocate **limited resources** efficiently by evaluating both **costs** and **outcomes** üí∞.

**Explanation**: Economic evaluation is a structured approach to compare healthcare interventions, such as a new drug versus standard treatment, by weighing their **financial costs** against their **health benefits**. In Malaysia, where healthcare budgets are constrained, this process is vital for ensuring that every ringgit spent delivers the **maximum health impact**. For example, deciding whether to fund a new cancer therapy requires analyzing not just the price of the drug but also the additional years of life or quality of life it provides. This **dual focus** on costs and outcomes makes economic evaluation a cornerstone of **evidence-based decision-making** in public health üåü.

### üìä Types of Economic Evaluation

Economic evaluations come in different forms, each suited to specific decision-making contexts. The table below summarizes the **four main types**, their **outcome measures**, and the **questions they answer**:

|**Type**|**Outcome Measure**|**Decision Focus**|
|---|---|---|
|**CMA**|Same outcomes|Which is cheaper?|
|**CEA**|Natural units (e.g., life-years gained)|Which gives more health for the cost?|
|**CUA**|Utility-based (e.g., QALYs, DALYs)|Which gives more value considering quality of life?|
|**CBA**|Money (e.g., RM)|Do monetary benefits exceed costs?|

- **Note**: **Cost-Minimization Analysis (CMA)** is rarely used unless **equivalency of outcomes** is proven.

**Elaboration**:

- **CMA (Cost-Minimization Analysis)**: Used when two interventions produce **identical outcomes**, focusing solely on which option is **less expensive**. For instance, if two drugs treat a condition equally well, CMA identifies the cheaper one. Its limited use stems from the difficulty of proving outcome equivalence üìâ.
- **CEA (Cost-Effectiveness Analysis)**: Measures outcomes in **natural units**, like life-years gained or cases prevented, making it ideal for comparing interventions with similar health goals. For example, CEA could compare two vaccines based on how many infections they prevent per ringgit spent ü©∫.
- **CUA (Cost-Utility Analysis)**: Incorporates **quality of life** using measures like **QALYs** (Quality-Adjusted Life Years) or **DALYs** (Disability-Adjusted Life Years). This is useful when interventions affect both **length** and **quality** of life, such as comparing cancer treatments with different side effects üåü.
- **CBA (Cost-Benefit Analysis)**: Converts all outcomes into **monetary terms**, allowing comparison across diverse interventions. For example, CBA might assess whether the economic benefits of a public health campaign (e.g., reduced sick days) outweigh its costs üí∏.
- **Key Insight**: The choice of evaluation type depends on the **decision context** and the **type of outcome** most relevant to stakeholders. In Malaysia, **CUA** is often used in health technology assessments (HTA) to balance quality of life with cost considerations.

### üß† Key Economic Principles

Economic evaluations are grounded in **fundamental economic principles** that guide resource allocation decisions in healthcare. These principles are essential for understanding **why** and **how** evaluations are conducted:

- **Scarcity**: Resources are **limited**, necessitating **choices** üìâ.
- **Opportunity Cost**: The **value** of the next best alternative forgone when a decision is made üí∏.
- **Efficiency**: Maximizing **health outcomes** per unit of resource üåü.
- **Marginal Analysis**: Evaluating the **incremental cost** and **effect** of a change in resource use üìà.

**Elaboration**:

- **Scarcity**: In Malaysia‚Äôs health system, budgets for hospitals, drugs, and preventive programs are finite. This forces decision-makers to prioritize interventions, such as choosing between expanding dialysis services or funding a vaccination program. **Scarcity** drives the need for economic evaluation to identify the **best use** of limited resources.
- **Opportunity Cost**: Every decision has a trade-off. For example, spending on a new cancer drug means forgoing funds for maternal health programs. The **opportunity cost** is the health benefits lost from the unchosen option, making it critical to evaluate whether the chosen intervention delivers greater value üí°.
- **Efficiency**: The goal is to achieve the **maximum health benefit** for every ringgit spent. Economic evaluation helps identify interventions that offer the **best health outcomes** relative to their costs, such as a cost-effective screening program that detects diseases early ü©∫.
- **Marginal Analysis**: Focuses on the **additional costs** and **benefits** of scaling up an intervention. For instance, adding more hospital beds may improve care, but marginal analysis assesses whether the extra cost is justified by the additional health gains üìä.

**Practical Application**: These principles underpin every economic evaluation, ensuring that decisions are **rational**, **transparent**, and aligned with the goal of **maximizing health** within budget constraints. In Malaysia, applying these principles helps policymakers navigate tough choices, such as prioritizing rural healthcare access over urban hospital upgrades.

### üëÅÔ∏è Importance of Perspective

- **Definition**: _Perspective defines whose costs and benefits are counted in an evaluation._
- **Impact**: Different perspectives yield **different conclusions** for the same intervention.
- **Common Perspectives**:

|**Perspective**|**Costs Included**|**Common Use**|
|---|---|---|
|**Societal**|All costs (direct, indirect, intangible)|Academics, global health agencies|
|**Health System/Provider**|Direct medical costs only|Ministries of Health, HTA bodies|
|**Payer**|Reimbursed/claimable medical expenses|Insurance schemes, MySalam, employers|
|**Patient**|Out-of-pocket costs, lost income|Advocacy groups, equity researchers|

**Elaboration**:

- **Perspective Defined**: The **perspective** determines the **scope** of an economic evaluation by specifying which **costs** (e.g., drug prices, travel expenses) and **benefits** (e.g., health gains, productivity) are included. Choosing the right perspective ensures the evaluation aligns with the **stakeholder‚Äôs priorities**.
- **Societal Perspective**: Captures **all costs and benefits**, including medical costs, patient travel, lost wages, and even intangible costs like pain. This broad view is favored by academics and global health agencies for its **comprehensive** approach, but it‚Äôs complex to implement due to data demands üåç.
- **Health System/Provider Perspective**: Focuses on **direct medical costs** (e.g., hospital stays, medications) borne by healthcare providers or the Ministry of Health. This is common in Malaysia‚Äôs HTA processes, as it reflects **budgetary constraints** of public healthcare systems ü©∫.
- **Payer Perspective**: Includes only **reimbursed costs**, such as those covered by insurance or schemes like MySalam. This perspective is relevant for insurers or employers managing healthcare claims üí∏.
- **Patient Perspective**: Centers on **out-of-pocket costs** (e.g., co-pays, transport) and **lost income** due to illness or treatment. This is critical for **equity studies**, highlighting the financial burden on patients, especially in low-income communities ‚öñÔ∏è.
- **Impact of Perspective**: The same intervention, like a new cancer drug, may appear **cost-effective** from a **societal perspective** (due to productivity gains) but **not cost-effective** from a **health system perspective** (due to high drug costs). In Malaysia, choosing the appropriate perspective is crucial for aligning evaluations with **policy goals**, such as improving access or controlling budgets.

**Example in Context**: Consider a mobile dental clinic for rural Malaysia. A **societal perspective** might justify its cost by including reduced travel expenses and improved productivity for patients. However, a **health system perspective** might focus only on the clinic‚Äôs operational costs, potentially deeming it too expensive. Understanding these differences helps policymakers interpret evaluation results accurately üìä.

### üìã Summary Table: Key Concepts in Economic Evaluation

|**Concept**|**Description**|**Relevance to Malaysia**|
|---|---|---|
|**Economic Evaluation**|Compares costs and consequences of interventions|Guides efficient resource allocation in a scarce healthcare system üí∞|
|**Types (CMA, CEA, CUA, CBA)**|Vary by outcome measure and decision focus|Enables tailored evaluations, e.g., CUA for quality-of-life-focused interventions ü©∫|
|**Principles**|Scarcity, opportunity cost, efficiency, marginal analysis|Ensures rational, evidence-based decisions under budget constraints üåü|
|**Perspective**|Defines whose costs/benefits are counted|Aligns evaluations with stakeholder needs, e.g., MOH or patients ‚öñÔ∏è|

---

## üìã 3. Steps in Conducting a Full Economic Evaluation

A **full economic evaluation** systematically compares **two or more interventions** to inform **resource allocation**, providing a structured approach to balance **costs** and **health benefits** in healthcare decision-making. The process involves **10 key steps**, each critical for ensuring **methodological rigor** and **policy relevance**. These steps guide public health professionals in Malaysia‚Äôs resource-constrained health system to make **evidence-based decisions** that maximize health outcomes while respecting budget limitations üåç. This section outlines each step with practical examples, ensuring students can apply these methods to real-world challenges like evaluating new vaccines or rural healthcare programs ü©∫.

### üîç Step 1: Define the Problem and Comparators

- **Objective**: Clearly state the **health issue** or **policy question** and identify **interventions** to compare.
- **Requirements**:
    - Interventions must be **clinically relevant** and **feasible**.
    - Comparators can include **new treatment** vs. **standard care** or **no intervention**.
- **Example**: Should Malaysia‚Äôs Ministry of Health adopt a new **HPV vaccine** for boys alongside girls? üíâ

**Elaboration**: The first step sets the foundation by framing the **health problem** and specifying the **interventions** under consideration. A well-defined problem ensures the evaluation addresses a **specific, actionable question**. For instance, the HPV vaccine example focuses on expanding vaccination to boys, comparing it to the existing girls-only program or no vaccination. **Clinical relevance** ensures the interventions are practical in Malaysia‚Äôs healthcare context, while **feasibility** considers factors like cost, infrastructure, and acceptability. This step is crucial for aligning the evaluation with **policy priorities**, such as reducing cervical cancer rates, and sets the scope for subsequent steps üìã.

### üëÅÔ∏è Step 2: Choose the Perspective

- **Purpose**: Determines which **costs** and **benefits** are included in the analysis.
- **Common Perspectives**:
    - **Societal**: All costs and outcomes (direct, indirect, intangible).
    - **Health System**: Direct medical costs (e.g., drugs, hospital stays).
    - **Payer**: Reimbursed costs (e.g., insurance claims).
    - **Patient**: Out-of-pocket costs and productivity losses.
- **Impact**: Perspective affects the **interpretation of value** (e.g., societal may favor interventions with productivity gains, while health system may prioritize budget impact).

**Elaboration**: Selecting a **perspective** defines the **lens** through which the evaluation views costs and benefits, directly influencing the results. For example, a **societal perspective** in the HPV vaccine case would include costs like lost productivity from cervical cancer and benefits like reduced healthcare costs across generations, making the vaccine appear more cost-effective. In contrast, a **health system perspective** might focus solely on vaccine procurement and delivery costs, potentially deeming it less affordable. In Malaysia, the **health system perspective** is often used by the Ministry of Health for budget-focused decisions, while the **patient perspective** highlights **equity** concerns, such as out-of-pocket expenses for rural communities. Choosing the right perspective ensures the evaluation aligns with the **stakeholder‚Äôs priorities**, enhancing its **policy relevance** üëÄ.

### ‚è∞ Step 3: Set the Time Horizon

- **Definition**: The **duration** over which **costs** and **outcomes** are measured.
- **Considerations**:
    - Must be **long enough** to capture **meaningful effects**.
    - **Short-term** (e.g., 1 year) for acute conditions.
    - **Long-term** (e.g., lifetime) for chronic diseases.
- **Risk**: A **short horizon** may miss **delayed benefits** or **costs**.
- **Example**: A **5-year horizon** for a mobile dental clinic may capture initial costs but miss long-term oral health gains.

**Elaboration**: The **time horizon** determines how far into the future the evaluation looks, impacting the **completeness** of the analysis. For acute conditions like influenza, a **1-year horizon** may suffice, but chronic diseases like diabetes or interventions like dental clinics require **long-term horizons** to capture outcomes such as reduced complications or improved quality of life. In the mobile dental clinic example, a **5-year horizon** might cover setup costs but fail to account for **long-term benefits** like fewer extractions or better oral health in rural areas. Choosing an **appropriate horizon** is critical in Malaysia, where **preventive interventions** often have delayed benefits that justify initial investments, ensuring evaluations don‚Äôt undervalue high-impact programs ‚è≥.

### üí∞ Step 4: Identify, Measure, and Value Costs

- **Types of Costs**:
    - **Direct Medical**: Hospital stays, drugs, staff time ü©∫.
    - **Direct Non-Medical**: Transport, caregiving üöó.
    - **Indirect**: Lost productivity due to illness or treatment üíº.
    - **Intangible**: Pain, anxiety (rarely quantified) üòü.
- **Process**:
    - Use **real-world data**, **costing studies**, or **tariffs** to ensure accuracy.
    - Align costs with the chosen **perspective**.
- **Importance**: Accurate cost data is **essential** for credible evaluations.

**Elaboration**: This step involves a **three-part process**: identifying **what** resources are used, **measuring** how much is used, and **valuing** those resources in monetary terms. For example, evaluating the HPV vaccine requires listing **direct medical costs** (vaccine doses, nurse time), **direct non-medical costs** (travel to clinics), **indirect costs** (parental time off work), and, if societal, **intangible costs** like anxiety about side effects. **Real-world data** from Malaysia‚Äôs healthcare system, such as hospital tariffs or costing studies, ensures accuracy, while aligning costs with the **perspective** (e.g., excluding patient travel in a health system perspective) maintains relevance. **Accurate costing** builds trust in the evaluation, especially for policymakers deciding whether to fund costly interventions üí∏.

### üìà Step 5: Identify and Measure Outcomes

- **Types**:
    - **Natural Units**: Cases detected, life-years gained (for CEA).
    - **Utility-Based**: QALYs, DALYs (for CUA).
    - **Monetary**: RM value (for CBA).
- **Requirements**:
    - Outcomes must be **meaningful**, **measurable**, and **valid**.
    - Choice of outcome determines the **evaluation type** (CEA, CUA, CBA).

**Elaboration**: Outcomes reflect the **health benefits** of an intervention, and selecting the right type is crucial for a **meaningful evaluation**. **Natural units** like life-years gained are used in **CEA** for straightforward comparisons, such as how many years the HPV vaccine extends life by preventing cancer. **Utility-based outcomes** like **QALYs** (Quality-Adjusted Life Years) or **DALYs** (Disability-Adjusted Life Years) are used in **CUA** to capture both **quantity** and **quality** of life, vital for interventions with side effects. **Monetary outcomes** in **CBA** convert benefits to ringgit, useful for cross-sector comparisons. In Malaysia, **QALYs** are common in health technology assessments, ensuring outcomes are **measurable** (via tools like EQ-5D) and **valid** (reflecting patient experiences). The outcome choice shapes the evaluation‚Äôs **focus** and **policy impact** üìä.

### ‚è≥ Step 6: Apply Discounting (If Needed)

- **Definition**: _Adjusting future costs and outcomes to their present value to reflect time preference (value now > value later)._
- **When Applied**: For **time horizons** exceeding **1 year**.
- **Common Discount Rates**: **3‚Äì5%** annually.
- **Purpose**: Ensures **fair comparison** between interventions with different timing of costs and benefits.
- **Example**: A **3% discount rate** reduces future QALYs and costs in long-term interventions like cancer treatment.

**Elaboration**: **Discounting** accounts for the **time value** of money and health benefits, recognizing that people prefer benefits now over later. For time horizons beyond **1 year**, a **3‚Äì5% annual discount rate** is applied, with Malaysia‚Äôs HTA often using **3%**. For instance, in a cancer treatment evaluation, future costs (e.g., follow-up care in year 5) and outcomes (e.g., QALYs gained) are discounted to their **present value**, ensuring a **fair comparison** with interventions yielding immediate benefits. In the HPV vaccine case, discounting reduces the value of future cancer prevention benefits, affecting cost-effectiveness. This step is critical for **long-term interventions** in Malaysia, where preventive programs like vaccinations require careful consideration of future impacts üï∞Ô∏è.

### üìä Step 7: Conduct Incremental Analysis

- **Definition**: _Compares the additional cost and benefit of one intervention versus another._
- **Tool**: **Incremental Cost-Effectiveness Ratio (ICER)**:  
    $$ \text{ICER} = \frac{\text{Cost}_A - \text{Cost}_B}{\text{Effect}_A - \text{Effect}_B} $$
    - **Numerator**: Incremental cost (RM).
    - **Denominator**: Incremental effectiveness (e.g., QALYs, life-years).
- **Interpretation**: Compare ICER against **thresholds** (e.g., willingness-to-pay, GDP-based, or opportunity cost-based).
- **Purpose**: Determines if the **extra cost** is worth the **extra benefit**.

**Elaboration**: **Incremental analysis** focuses on the **additional** costs and benefits of one intervention over another, using the **ICER** to quantify value. The formula, $$ \text{ICER} = \frac{\text{Cost}_A - \text{Cost}_B}{\text{Effect}_A - \text{Effect}_B} $$, calculates the cost per additional unit of effectiveness (e.g., RM per QALY). For the HPV vaccine, if vaccinating boys costs RM 10 million more but yields 1,000 additional QALYs, the ICER is RM 10,000/QALY. This is compared to **thresholds** like Malaysia‚Äôs GDP-based threshold (RM 50,000‚Äì150,000/QALY) to assess cost-effectiveness. In Malaysia, ICERs guide **resource allocation**, helping policymakers decide whether the **extra cost** justifies the **health gains**, especially for high-cost interventions like new drugs üìà.

### üî¨ Step 8: Perform Sensitivity Analysis

- **Purpose**: Tests how **results change** under **uncertainty** in parameters (e.g., costs, outcomes).
- **Types**:
    - **One-Way**: Vary one parameter at a time.
    - **Multi-Way**: Vary multiple parameters simultaneously.
    - **Probabilistic**: Use Monte Carlo simulations with parameter distributions.
- **Benefits**:
    - Identifies **key drivers** of cost-effectiveness.
    - Enhances **confidence** in conclusions by assessing robustness.

**Elaboration**: **Sensitivity analysis** addresses **uncertainty** in data, such as fluctuating drug prices or variable health outcomes, ensuring evaluations are **robust**. **One-way analysis** tests a single parameter, like vaccine cost, to see its impact on the ICER. **Multi-way analysis** combines multiple changes, such as cost and efficacy. **Probabilistic analysis** uses simulations to model real-world variability, providing a range of possible ICERs. In the HPV vaccine case, sensitivity analysis might reveal that cost-effectiveness hinges on vaccine price, guiding negotiations with suppliers. In Malaysia, this step builds **confidence** in policy recommendations, ensuring decisions hold up under varying conditions üîç.

### üßÆ Step 9: Use Modeling (If Applicable)

- **Purpose**: Simulates **complex** or **long-term** scenarios where direct data are limited.
- **Tools**:
    - **Decision Trees**: For short-term, one-time decisions.
    - **Markov Models**: For chronic or recurring conditions.
- **Role**: Bridges **data gaps**, supports **extrapolation**, and incorporates **uncertainty**.

**Elaboration**: **Modeling** creates **simplified representations** of complex healthcare scenarios, especially when trial data is limited. **Decision trees** are ideal for short-term decisions, like choosing between two surgical procedures, mapping out possible outcomes. **Markov models** suit chronic conditions, like cancer, by tracking patients through health states (e.g., healthy, diseased, dead) over time. For the HPV vaccine, a Markov model might simulate long-term cancer prevention, filling **data gaps** from short-term trials. In Malaysia, modeling is crucial for **preventive interventions**, allowing policymakers to project long-term benefits and costs, enhancing **decision-making** üìä.

### üìú Step 10: Interpret and Present Results

- **Methods**:
    - Use **cost-effectiveness planes**, **league tables**, or **net benefit** analyses.
    - Report **clearly**, **transparently**, and with **context**.
- **Alignment**: Results must align with **policy priorities** and **resource constraints**.
- **Goal**: Inform **action**, not just analysis.

**Elaboration**: The final step translates **complex data** into **actionable insights**. **Cost-effectiveness planes** visualize ICERs, showing whether an intervention is cost-effective. **League tables** rank interventions by cost-effectiveness, while **net benefit analyses** quantify value in monetary terms. **Clear, transparent reporting** ensures stakeholders understand assumptions and limitations, aligning results with Malaysia‚Äôs **policy priorities** like equity or budget control. For the HPV vaccine, presenting the ICER relative to Malaysia‚Äôs GDP threshold informs whether to fund it, driving **policy action** rather than just academic analysis üì¢.

### üìã Summary of Steps

The table below summarizes the **10 steps**, providing a quick reference for conducting a full economic evaluation:

|**Step**|**Description**|
|---|---|
|1. Define Problem & Comparators|State health issue, identify interventions|
|2. Choose Perspective|Select whose costs/benefits to include|
|3. Set Time Horizon|Determine duration for analysis|
|4. Identify, Measure, Value Costs|Quantify resource use and assign monetary value|
|5. Identify & Measure Outcomes|Select meaningful, measurable outcomes|
|6. Apply Discounting|Adjust future values to present|
|7. Conduct Incremental Analysis|Calculate ICER|
|8. Perform Sensitivity Analysis|Test result robustness|
|9. Use Modeling|Simulate complex scenarios|
|10. Interpret & Present Results|Report findings clearly|

**Elaboration**: This table serves as a **roadmap** for evaluations, ensuring each step is addressed systematically. Each step builds on the previous, creating a **cohesive process** that balances **scientific rigor** with **practical applicability**. In Malaysia, following these steps ensures evaluations are **comprehensive** and **relevant**, guiding decisions on interventions like new treatments or public health programs üåü.

### üìä Case Example: Mobile Dental Clinic

- **Scenario**: Malaysia‚Äôs Ministry of Health considers a **mobile dental clinic** for rural areas vs. a **fixed subsidy scheme**.
- **Application**:

|**Step**|**Example**|
|---|---|
|Define Problem|Limited rural dental access; compare mobile clinic vs. subsidy scheme|
|Perspective|Health system perspective|
|Time Horizon|5 years|
|Identify Costs|Mobile van purchase, fuel, salaries vs. per-patient subsidies|
|Identify Outcomes|Cavities treated, QALYs gained|
|Discounting|Apply **3%** per annum|
|Incremental Analysis|ICER = RM per cavity treated or QALY|
|Sensitivity Analysis|Test variation in staff costs, fuel prices|
|Modeling|Use decision tree if data incomplete|
|Interpretation|Present ICER relative to GDP|

**Elaboration**: This case illustrates how the **10 steps** apply to a real-world problem in Malaysia. The **problem** of limited dental access in rural areas prompts comparison of a **mobile clinic** (costly but accessible) versus a **subsidy scheme** (cheaper but less comprehensive). The **health system perspective** focuses on direct costs like van maintenance or subsidies. A **5-year horizon** captures initial costs, but **discounting** at **3%** adjusts future benefits like improved oral health. The **ICER** quantifies cost per QALY or cavity treated, with **sensitivity analysis** testing uncertainties like fuel costs. A **decision tree** models outcomes if data is sparse, and results are presented relative to Malaysia‚Äôs GDP, informing whether the clinic is **cost-effective**. This example demonstrates the **practicality** of the steps in addressing **equity** and **access** challenges in Malaysia‚Äôs healthcare system ü¶∑.

---

## üí∞ 4. Costing in Economic Evaluation

Costing is a cornerstone of **economic evaluation**, providing the foundation for assessing the **resource implications** of healthcare interventions. This section explores the **definition**, **types**, **processes**, and **approaches** to costing, emphasizing the need for **accuracy** and **relevance** in Malaysia‚Äôs resource-constrained healthcare system üåç. By systematically identifying, measuring, and valuing costs, public health professionals can ensure evaluations reflect the **true economic impact** of interventions, guiding **efficient resource allocation** for policies like cancer treatment or rural healthcare programs ü©∫.

### üìñ What is Cost?

- **Definition**: _The value of resources consumed to deliver an intervention or service._
- **Importance**: Systematic **identification**, **measurement**, and **valuation** of costs ensure accurate reflection of **resource use** from the chosen perspective.

**Elaboration**: In economic evaluation, a **cost** represents the **monetary value** of all resources used to implement a healthcare intervention, such as drugs, staff time, or patient travel. This step is critical because **accurate costing** underpins the credibility of the evaluation, ensuring decision-makers in Malaysia‚Äôs health system understand the **financial burden** of interventions. For example, costing a new vaccine program requires capturing not just the vaccine price but also delivery costs and potential productivity losses, depending on the perspective. By systematically addressing costs, evaluations align with **policy goals**, such as maximizing health outcomes within limited budgets üí∞.

### üìã Types of Costs

The table below outlines the **four types of costs** in economic evaluation, each with distinct characteristics and examples relevant to healthcare:

|**Cost Type**|**Description**|**Medical Example**|
|---|---|---|
|**Direct Medical**|Costs incurred by the health system/provider|Chemotherapy drugs, oncologist fees, infusion room, lab tests|
|**Direct Non-Medical**|Non-medical expenses due to seeking care|Patient travel to oncology center, parking, accommodation|
|**Indirect**|Productivity losses due to illness/treatment|Sick leave during chemo cycles, early retirement due to fatigue|
|**Intangible**|Non-financial costs hard to quantify|Anxiety, pain, hair loss stigma, emotional distress|

**Elaboration**:

- **Direct Medical Costs**: These are expenses borne by the **health system** or **providers**, such as the cost of chemotherapy drugs, oncologist consultations, or hospital facilities. In Malaysia, these are critical for **health system perspective** evaluations, as they reflect the **budget impact** on public hospitals ü©∫.
- **Direct Non-Medical Costs**: These include expenses patients incur to access care, like travel to a cancer center or accommodation for distant treatments. These are relevant in **societal** or **patient perspectives**, highlighting **access barriers** in rural Malaysia üöó.
- **Indirect Costs**: These capture **productivity losses**, such as time off work during treatment or early retirement due to illness. In Malaysia, where workforce productivity is vital, these costs are significant in **societal perspective** evaluations üíº.
- **Intangible Costs**: These non-financial costs, like pain or emotional distress, are challenging to quantify but critical for understanding the **full impact** of interventions, especially in **societal perspective**. For example, the stigma of hair loss from chemotherapy can affect patient well-being üòü.
- **Key Insight**: The type of cost included depends on the **perspective**, ensuring evaluations reflect the **stakeholder‚Äôs priorities**, such as budget control for the Ministry of Health or equity for patients.

### üîç Costing Process: 3 Steps

The costing process involves three systematic steps to ensure **accuracy** and **relevance**:

1. **Identification**:
    - **What resources** are used?
    - List all relevant **resource items** for both **intervention** and **comparator**.
    - **Example**: Number of **chemo sessions**, **blood tests**, **clinic visits**.
2. **Measurement**:
    - **How much** was used?
    - Quantify **resource use** (e.g., number of visits, days hospitalized).
    - **Data Sources**: Patient records, surveys, administrative databases.
    - **Example**: **6 chemo cycles**, **12 blood tests**.
3. **Valuation**:
    - Assign a **monetary value** to each resource unit.
    - **Example**: RM 1,500 per chemo cycle, RM 80 per lab test, RM 50 per outpatient visit.
    - **Sources**: Fee schedules, Diagnostic-Related Group (DRG) tariffs, market prices, published cost studies.

**Elaboration**:

- **Identification**: This step involves listing **all resources** consumed by both the intervention and comparator. For a chemotherapy program, this includes drugs, lab tests, and clinic visits. In Malaysia, accurate identification ensures evaluations capture **context-specific costs**, such as public hospital tariffs versus private sector rates üìã.
- **Measurement**: Quantifying **resource use** requires precise data on quantities, such as the number of chemotherapy cycles or hospital days. **Data sources** like patient records or Malaysia‚Äôs health system databases (e.g., hospital billing systems) ensure reliability. For example, measuring **6 chemo cycles** and **12 blood tests** provides a clear picture of resource consumption üìä.
- **Valuation**: Assigning **monetary values** converts resource use into ringgit, using sources like **DRG tariffs** or **market prices**. In Malaysia, standard fee schedules from the Ministry of Health or published cost studies ensure consistency. For instance, valuing a chemo cycle at RM 1,500 aligns with local pricing, making the evaluation **credible** üí∏.
- **Importance**: This three-step process ensures **systematic costing**, aligning with the chosen **perspective** and providing a **transparent** basis for comparing interventions.

### üìä Micro-Costing vs. Gross-Costing

The table below compares **micro-costing** and **gross-costing**, highlighting their differences and appropriate use cases:

|**Approach**|**Description**|**Use When**|
|---|---|---|
|**Micro-Costing**|Itemize and value each resource in detail|High precision needed (e.g., alongside clinical trials)|
|**Gross-Costing**|Use average cost per service unit|Budget planning, secondary data|

- **Micro-Costing**: More **precise** but **time-consuming**.
- **Gross-Costing**: **Quicker** but **less detailed**.

**Elaboration**:

- **Micro-Costing**: This approach involves detailed itemization of every resource, such as the cost of each drug, test, or staff hour in a clinical trial. It‚Äôs ideal for **high-precision** evaluations, like assessing a new cancer drug in Malaysia‚Äôs public hospitals, but requires significant time and data üìè.
- **Gross-Costing**: Uses **average costs** per service unit, such as the cost per hospital admission, making it faster and suitable for **budget planning** or when detailed data is unavailable. In Malaysia, gross-costing might be used for national health program evaluations, relying on average costs from administrative data üìà.
- **Trade-Offs**: **Micro-costing** offers greater accuracy but is resource-intensive, while **gross-costing** is efficient but less granular. The choice depends on the evaluation‚Äôs **goals** and **data availability**, with Malaysia‚Äôs HTA often favoring micro-costing for critical interventions like new therapies.

### üìà Example: Breast Cancer Treatment

- **Policy Question**: Is **Drug A** (new monoclonal antibody) more cost-effective than **Drug B** (standard chemotherapy) for HER2+ breast cancer?
- **Costs to Include**:
    - **Drug Acquisition**: RM 5,000 vs. RM 1,200 per cycle.
    - **Pre-Medication & Monitoring Labs**.
    - **Side Effect Management**: E.g., febrile neutropenia admission.
    - **Patient Travel & Lost Income**: If using **societal** or **patient** perspective.
- **Key Insight**: Accurate costing requires understanding **what**, **how much**, **at what price**, and **whose perspective** counts.

**Elaboration**: This example illustrates the **costing process** in a real-world scenario. For **Drug A** (a new monoclonal antibody) versus **Drug B** (standard chemotherapy), costing involves identifying resources like **drug acquisition** (RM 5,000 vs. RM 1,200 per cycle), **pre-medication**, and **lab tests** for monitoring. **Side effect management**, such as hospital admissions for febrile neutropenia, is critical, especially for chemotherapy with severe side effects. If using a **societal** or **patient perspective**, costs like **travel to cancer centers** and **lost income** from missed work are included, reflecting the **financial burden** on patients in Malaysia, particularly in rural areas. The **key insight** is that accurate costing hinges on understanding the **resources used**, their **quantity**, their **monetary value**, and the **perspective**, ensuring the evaluation is **relevant** and **credible** for decision-makers ü©∫.

### üëÅÔ∏è Perspective-Specific Costs

- **HER2+ Breast Cancer Example**:

|**Cost Item**|**Included in Perspective**|
|---|---|
|Drug price (RM per cycle)|All perspectives|
|Blood tests, infusion costs|Provider, Payer, Societal|
|Travel to cancer center|Patient, Societal|
|Lost income from work|Patient, Societal|

- **Implications**:

|**Perspective**|**ICER Interpretation**|
|---|---|
|**Societal**|High drug cost offset by return to work ‚Üí **Cost-effective**|
|**Health System**|Costly without budget impact benefit ‚Üí **Not cost-effective**|
|**Patient**|High OOP costs ‚Üí **Financially toxic**|
|**Payer**|High reimbursement burden ‚Üí **Low priority**|

**Elaboration**: The **perspective** shapes which costs are included, significantly affecting the **cost-effectiveness** of an intervention. For the HER2+ breast cancer case, **drug prices** are relevant across all perspectives, as they impact budgets universally. **Blood tests** and **infusion costs** are included in **provider**, **payer**, and **societal perspectives**, reflecting costs to hospitals or insurers. **Travel** and **lost income** are only relevant in **patient** or **societal perspectives**, highlighting **equity concerns** for Malaysian patients who may face significant out-of-pocket expenses. The **implications** are profound: a **societal perspective** might find Drug A **cost-effective** due to productivity gains, while a **health system perspective** might reject it due to high drug costs. A **patient perspective** could reveal **financial toxicity**, critical for **equity-focused** policies, while a **payer perspective** might prioritize interventions with lower reimbursement burdens. In Malaysia, understanding these differences ensures evaluations align with **stakeholder needs**, from budget control to patient welfare ‚öñÔ∏è.

---

## üìä 5. Measuring Outcomes

Measuring **outcomes** is a critical component of **economic evaluation**, as it quantifies the **health benefits** of healthcare interventions. This section explores the **definition**, **types**, and **measurement methods** for outcomes, emphasizing their role in informing **policy decisions** in Malaysia‚Äôs resource-constrained healthcare system üåç. By selecting and measuring outcomes that are **meaningful**, **measurable**, and **valid**, public health professionals can ensure evaluations reflect the **true value** of interventions, guiding decisions on programs like cancer treatments or preventive health measures ü©∫.

### üìñ What are Outcomes?

- **Definition**: _The consequences of an intervention on health._
- **Measurement**: Varies by **evaluation type** (CEA, CUA, CBA).

**Elaboration**: In economic evaluation, **outcomes** represent the **health impacts** of an intervention, such as extended life, improved quality of life, or economic benefits like return to work. The choice of outcome measure depends on the **type of evaluation**‚ÄîCost-Effectiveness Analysis (CEA), Cost-Utility Analysis (CUA), or Cost-Benefit Analysis (CBA)‚Äîeach addressing different **decision-making needs**. In Malaysia, where **health system efficiency** and **equity** are priorities, selecting the right outcome ensures evaluations align with **policy goals**, such as improving survival rates for cancer patients or reducing disease burden in rural communities. Accurate outcome measurement provides a **clear picture** of an intervention‚Äôs value, making it essential for **evidence-based decisions** üìà.

### üìã Types of Outcome Measures

The table below summarizes the **three main types of outcome measures**, their use in specific evaluation types, and examples relevant to healthcare:

|**Outcome Type**|**Used In**|**Example**|
|---|---|---|
|**Natural Units**|CEA|Life-years gained, cases detected|
|**Utility-Based**|CUA|QALYs, DALYs|
|**Monetary**|CBA|RM value of productivity|

**Elaboration**:

- **Natural Units (CEA)**: Used in **Cost-Effectiveness Analysis**, these measure health outcomes in **tangible, physical units**, such as life-years gained or cases detected. For example, a vaccination program might be evaluated based on the number of infections prevented, making it ideal for interventions with clear, measurable health impacts. In Malaysia, CEA is commonly used to compare treatments with similar goals, such as two drugs for hypertension, focusing on **health gains per ringgit** spent ü©∫.
- **Utility-Based (CUA)**: Used in **Cost-Utility Analysis**, these outcomes, like **Quality-Adjusted Life Years (QALYs)** or **Disability-Adjusted Life Years (DALYs)**, combine **length** and **quality of life**. This is critical for interventions affecting **quality of life**, such as cancer therapies with different side effects. In Malaysia‚Äôs health technology assessments (HTA), QALYs are widely used to balance **health benefits** with **quality of life**, ensuring patient-centered evaluations üåü.
- **Monetary (CBA)**: Used in **Cost-Benefit Analysis**, these convert health outcomes into **monetary terms**, such as the economic value of returning to work after treatment. This allows comparison across diverse sectors, like healthcare versus education. In Malaysia, CBA might assess a public health campaign‚Äôs economic benefits, such as reduced sick leave, against its costs üí∏.
- **Key Insight**: The choice of outcome type shapes the **evaluation‚Äôs focus** and **policy relevance**, ensuring alignment with Malaysia‚Äôs health priorities, such as improving **access** or **quality of care**.

### üìà Breast Cancer Case: Outcome Examples

- **Comparing Drug A (targeted therapy) vs. Drug B (standard chemotherapy)**:

|**Evaluation**|**Outcome Used**|**Why It Matters**|
|---|---|---|
|**CEA**|Life-years gained|Drug A improves survival by 8 months|
|**CUA**|QALYs|Drug A improves survival with fewer side effects, enhancing quality of life|
|**CBA**|RM value of productivity|Drug A allows earlier return to work|

**Elaboration**: This case illustrates how **outcome measures** vary by evaluation type in a real-world scenario. For **HER2+ breast cancer**, comparing **Drug A** (targeted therapy) and **Drug B** (standard chemotherapy) involves different outcomes:

- **CEA**: Focuses on **life-years gained**, as Drug A extends survival by **8 months** compared to Drug B. This is crucial for assessing whether the additional survival justifies Drug A‚Äôs higher cost, a key consideration for Malaysia‚Äôs health system when allocating budgets ü©∫.
- **CUA**: Uses **QALYs** to account for both **survival** and **quality of life**. Drug A‚Äôs fewer side effects (e.g., less nausea) improve quality of life, yielding more QALYs. In Malaysia, where patient well-being is a priority, CUA highlights interventions that balance **quantity** and **quality** of life üåü.
- **CBA**: Measures the **RM value of productivity**, as Drug A allows patients to return to work sooner, reducing economic losses. This is relevant for **societal perspective** evaluations in Malaysia, where workforce productivity impacts national development üíº.
- **Why It Matters**: The choice of outcome influences the **perceived value** of Drug A, guiding policymakers on whether its benefits outweigh its costs in Malaysia‚Äôs context.

### üß† Quality-Adjusted Life Year (QALY)

- **Definition**: _Combines length of life and quality of life on a scale from 0 (death) to 1 (perfect health)._
- **Examples**:
    - 1 year at **full health** = **1 QALY**.
    - 1 year with **side effects** (utility = 0.6) = **0.6 QALYs**.
- **Use Case**: CUA, especially when **quality of life** is significantly affected (e.g., chemotherapy vs. targeted therapy).

**Elaboration**: The **Quality-Adjusted Life Year (QALY)** is a widely used metric in **Cost-Utility Analysis**, integrating **life expectancy** and **quality of life** into a single measure. On the QALY scale, **0 represents death**, and **1 represents perfect health**, with values in between reflecting health states with impairments. For example, living **1 year** with **full health** yields **1 QALY**, while **1 year** with side effects (e.g., fatigue from chemotherapy, utility = 0.6) yields **0.6 QALYs**. In Malaysia, QALYs are critical for evaluating interventions like **targeted therapies** versus **chemotherapy**, where side effects significantly impact **quality of life**. By capturing both **quantity** and **quality**, QALYs provide a **patient-centered** measure, aligning with Malaysia‚Äôs focus on improving health outcomes and patient well-being in HTA processes üåü.

### üîç Measuring Utilities

The table below outlines **methods** for measuring utilities, which assign numerical values to health states:

|**Method**|**Description**|
|---|---|
|**EQ-5D**|Standardized tool for health states|
|**Time Trade-Off**|Time willing to trade for better health|
|**Standard Gamble**|Risk willing to accept for full health|

- **Sources**: Published **utility weights** or **patient-collected data**.

**Elaboration**:

- **EQ-5D**: A **standardized questionnaire** assessing health across five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Widely used in Malaysia‚Äôs HTA, it provides **reliable utility scores** for conditions like cancer or diabetes, ensuring consistency across studies üìã.
- **Time Trade-Off (TTO)**: Patients indicate how much **time** they‚Äôd sacrifice to live in better health (e.g., trading 10 years with pain for 8 years in perfect health). This method captures **patient preferences**, making it valuable for personalized evaluations in Malaysia üï∞Ô∏è.
- **Standard Gamble (SG)**: Patients choose between a certain health state and a gamble for **full health** versus **death**, reflecting their **risk tolerance**. This is less common but useful for severe conditions where patients weigh significant risks üí°.
- **Sources**: **Published utility weights** from global databases (e.g., EQ-5D norms) provide standardized values, while **patient-collected data** via surveys ensure **context-specific** utilities, critical for Malaysia‚Äôs diverse population. For example, utility scores for chemotherapy side effects might differ between urban and rural patients due to access or cultural factors.
- **Key Insight**: These methods ensure utilities are **valid** and **measurable**, enabling accurate QALY calculations for **CUA** in Malaysia‚Äôs health system.


---

## ‚è∞ 6. Time-Related Considerations

Time is a critical factor in **economic evaluation**, as the **timing** of costs and outcomes significantly impacts their perceived value. This section explores **time preference**, **discounting**, and **time horizon**, emphasizing their role in ensuring **fair comparisons** in Malaysia‚Äôs resource-constrained healthcare system üåç. By addressing **when** costs and benefits occur, public health professionals can accurately assess interventions like cancer treatments or preventive programs, ensuring evaluations reflect **long-term impacts** and guide **efficient resource allocation** ü©∫.

### üìñ Why Timing Matters

- **Time Preference**: People value **benefits now** more than later, necessitating adjustments for **future costs** and **outcomes**.

**Elaboration**: **Time preference** reflects the human tendency to prioritize **immediate benefits** over future ones, a principle rooted in economics. For example, a patient may value immediate relief from a treatment more than future health gains, and policymakers may prioritize current budget savings over long-term health improvements. In Malaysia‚Äôs healthcare context, this preference is critical when evaluating interventions like vaccinations, where costs are incurred now but benefits, such as reduced disease incidence, occur years later. Adjusting for **time preference** ensures evaluations are **realistic** and **relevant**, aligning with the priorities of stakeholders like the Ministry of Health or patients üìÖ.

### üìã Discounting

- **Definition**: _A method to adjust future costs and outcomes to their present value._
- **When Applied**: Time horizons **exceeding 1 year**.
- **Purpose**: Ensures **fair comparison** between interventions with different **timing** of costs and benefits.
- **Standard Discount Rates**:

|**Context**|**Common Rate**|
|---|---|
|High-income settings (e.g., UK, US)|**3%** annually|
|LMIC guidelines / WHO|**3‚Äì5%**|
|Malaysian HTA (MaHTAS)|Often **3%** for costs and benefits|

- **Example**: Breast Cancer Case:

|**Metric**|**Without Discounting**|**With 3% Discounting**|
|---|---|---|
|Survival Gain|0.8 QALYs|~0.76 QALYs|
|Productivity Gains|RM 20,000|~RM 18,500|

- **Insight**: Discounting **reduces** future health and financial benefits.

**Elaboration**: **Discounting** converts **future costs** and **outcomes** to their **present value**, reflecting the **time value of money** and health benefits. This is essential for time horizons **exceeding 1 year**, as it ensures **fair comparisons** between interventions with different timing. For instance, a cancer treatment with high upfront costs but benefits over decades is compared equitably with a treatment offering immediate benefits. In Malaysia, the **3% discount rate** recommended by the Malaysian Health Technology Assessment Section (MaHTAS) is commonly used, aligning with **low- and middle-income country (LMIC)** guidelines (3‚Äì5%) and high-income settings like the UK or US (3%). The breast cancer example shows that a **3% discount rate** reduces a **0.8 QALY** survival gain to **~0.76 QALYs** and **RM 20,000** in productivity gains to **~RM 18,500**, highlighting how discounting **lowers the value** of future benefits. This step is crucial in Malaysia for evaluating **long-term interventions** like preventive vaccinations, ensuring **cost-effectiveness** reflects **present-day value** üï∞Ô∏è.

### ‚è≥ Time Horizon

- **Definition**: _The length of time over which costs and outcomes are measured._
- **Choosing a Horizon**:

|**Scenario**|**Recommended Horizon**|
|---|---|
|Acute illness (e.g., influenza)|**1 year or less**|
|Chronic disease (e.g., cancer, diabetes)|**Lifetime** or **10‚Äì20 years**|
|Preventive intervention|Until **key outcomes** occur (e.g., cancer incidence avoided)|

- **Implications**: Breast Cancer Example:
    - **Short Horizon (1‚Äì2 years)**: Captures drug costs but misses survival gains.
    - **Lifetime Horizon**: Captures **reduced recurrence**, **survival**, and **return to work**.
    - **Risk**: Underestimating the horizon biases against **long-term interventions**.

**Elaboration**: The **time horizon** defines the **duration** over which an evaluation tracks **costs** and **outcomes**, directly affecting its **completeness**. For **acute illnesses** like influenza, a **1-year horizon** is sufficient, as costs and benefits occur quickly. For **chronic diseases** like cancer or diabetes, a **lifetime** or **10‚Äì20 year** horizon is needed to capture long-term effects like survival or complications. **Preventive interventions**, such as HPV vaccination, require a horizon extending until **key outcomes** (e.g., reduced cancer incidence) are realized, often decades later. In the breast cancer example, a **short horizon (1‚Äì2 years)** captures **drug costs** but misses **survival gains** or **reduced recurrence**, potentially undervaluing a targeted therapy. A **lifetime horizon** includes **long-term benefits** like extended survival and return to work, critical for assessing **cost-effectiveness** in Malaysia‚Äôs health system. The **risk** of a short horizon is **bias** against interventions with delayed benefits, such as preventive programs, which are vital for Malaysia‚Äôs public health strategy. Choosing an **appropriate horizon** ensures evaluations are **comprehensive** and **policy-relevant**, supporting decisions that maximize **health impact** üìä.

---

## üìà 7. Incremental Analysis and ICER

**Incremental analysis** is a cornerstone of **economic evaluation**, enabling decision-makers to compare the **additional costs** and **benefits** of one healthcare intervention over another. This section explores the **Incremental Cost-Effectiveness Ratio (ICER)**, its calculation, interpretation, and application in Malaysia‚Äôs resource-constrained healthcare system üåç. By quantifying the **cost per additional unit of health benefit**, ICER guides policymakers in assessing whether interventions like new cancer drugs are worth the investment, ensuring **efficient** and **equitable** resource allocation ü©∫.

### üìñ What is Incremental Analysis?

- **Definition**: _Compares the additional cost and benefit of one intervention versus another._
- **Question**: _‚ÄúHow much more are we paying for each additional unit of outcome?‚Äù_

**Elaboration**: **Incremental analysis** focuses on the **difference** in costs and outcomes between two interventions, such as a new drug versus standard care. This approach answers a critical question: **Is the extra cost justified by the extra benefit?** In Malaysia, where healthcare budgets are limited, this analysis is vital for prioritizing interventions that deliver the **greatest health impact** per ringgit spent. For example, comparing a new cancer therapy to an existing one involves assessing whether the additional cost leads to significant health gains, guiding decisions that balance **efficiency** and **patient outcomes** üìä.

### üßÆ ICER Formula

- **Formula**:  
    $$\text{ICER} = \frac{\text{Cost}_{\text{New}} - \text{Cost}_{\text{Comparator}}}{\text{Effect}_{\text{New}} - \text{Effect}_{\text{Comparator}}}$$
    - **Numerator**: Incremental cost (RM).
    - **Denominator**: Incremental effectiveness (e.g., QALYs, life-years).

**Elaboration**: The **Incremental Cost-Effectiveness Ratio (ICER)** quantifies the **additional cost** per **additional unit of health benefit** when choosing one intervention over another. The **numerator** represents the **difference in costs** (in Malaysian Ringgit, RM), while the **denominator** measures the **difference in effectiveness**, such as Quality-Adjusted Life Years (QALYs) or life-years gained. For instance, if a new drug costs RM 10,000 more but provides 0.5 additional QALYs, the ICER is calculated as $$\frac{10,000}{0.5} = \text{RM 20,000 per QALY}$$. In Malaysia, ICER is a key tool for **health technology assessments (HTA)**, helping policymakers determine whether the **extra cost** is worth the **health gain** in a resource-scarce environment üßÆ.

### üìä Example: HER2+ Breast Cancer

- **Data**:

|**Option**|**Cost (RM)**|**QALYs Gained**|
|---|---|---|
|Drug B (Standard)|20,000|1.5|
|Drug A (Targeted)|60,000|2.0|

- **Calculation**:  
    $$\text{ICER} = \frac{60,000 - 20,000}{2.0 - 1.5} = \frac{40,000}{0.5} = \text{RM 80,000 per QALY}$$

**Elaboration**: This example applies **incremental analysis** to compare **Drug A** (a targeted therapy) versus **Drug B** (standard chemotherapy) for **HER2+ breast cancer**. The **incremental cost** is RM 60,000 - RM 20,000 = **RM 40,000**, and the **incremental effectiveness** is 2.0 QALYs - 1.5 QALYs = **0.5 QALYs**. Using the ICER formula, $$\text{ICER} = \frac{40,000}{0.5} = \text{RM 80,000 per QALY}$$, this result indicates that adopting Drug A costs an additional **RM 80,000** for each QALY gained. In Malaysia, this ICER is compared to **thresholds** to determine **cost-effectiveness**, guiding decisions on whether to fund Drug A within the public health system‚Äôs budget constraints ü©∫.

### üîç Interpreting ICER

- **Threshold Comparison**:
    - **ICER < Threshold**: Intervention is **cost-effective**.
    - **ICER > Threshold**: May not be cost-effective, depending on context.
- **Threshold Types**:

|**Type**|**Value (Approx.)**|
|---|---|
|GDP per capita (1√ó)|~RM 50,000/QALY|
|GDP per capita (3√ó)|~RM 150,000/QALY|
|MOH/HTA Implied WTP|RM 90,000‚Äì120,000/QALY|
|Opportunity Cost-Based|~RM 30,000‚Äì50,000/QALY|

- **Malaysia Context**:
    - **WHO-CHOICE**: <1√ó GDP (~~RM 50,000) = **highly cost-effective**; 1‚Äì3√ó (~~RM 50,000‚Äì150,000) = **cost-effective**.
    - **Critique**: GDP-based thresholds are **simplistic**, ignoring **budget constraints** and **opportunity costs**.
    - **Opportunity Cost-Based**: Reflects **health gains forgone** when diverting resources (more context-sensitive).

**Elaboration**: **Interpreting the ICER** involves comparing it to a **threshold**, which represents the **maximum amount** a health system or society is willing to pay for an additional unit of health benefit (e.g., 1 QALY). If the ICER is **below the threshold**, the intervention is deemed **cost-effective**; if **above**, it may not be, depending on factors like **disease severity** or **budget availability**. In Malaysia, thresholds include:

- **GDP-based thresholds** from WHO-CHOICE: An ICER below **RM 50,000/QALY** (1√ó GDP per capita) is **highly cost-effective**, while **RM 50,000‚Äì150,000/QALY** (1‚Äì3√ó GDP) is **cost-effective**. However, these are criticized for being **simplistic**, as they don‚Äôt account for **budget constraints** or **local priorities**.
- **MOH/HTA Implied Willingness-to-Pay (WTP)**: Malaysia‚Äôs Ministry of Health and HTA often use an informal range of **RM 90,000‚Äì120,000/QALY**, reflecting practical budgetary considerations.
- **Opportunity Cost-Based Thresholds**: Estimated at **RM 30,000‚Äì50,000/QALY**, these reflect the **health gains forgone** when resources are diverted, offering a **context-sensitive** measure for Malaysia‚Äôs health system.

For the HER2+ breast cancer case, an ICER of **RM 80,000/QALY** is **cost-effective** under the **MOH/HTA WTP threshold** (RM 90,000‚Äì120,000) but **borderline** under the **1√ó GDP threshold** (RM 50,000) and **not cost-effective** under **opportunity cost-based thresholds** (RM 30,000‚Äì50,000). This highlights the need for **context-specific interpretation** to guide **policy decisions** in Malaysia üìä.

### üìà Cost-Effectiveness Plane

- **Quadrants**:
    - **NE (Northeast)**: More costly, more effective (evaluate ICER).
    - **SE (Southeast)**: Less costly, more effective (**adopt**).
    - **SW (Southwest)**: Less costly, less effective (evaluate trade-offs).
    - **NW (Northwest)**: More costly, less effective (**reject**).
- **Implication**: Drug A‚Äôs **RM 80,000/QALY** in the NE quadrant requires threshold comparison.

**Elaboration**: The **cost-effectiveness plane** is a visual tool that plots interventions based on their **incremental costs** (y-axis) and **incremental effectiveness** (x-axis), dividing outcomes into **four quadrants**:

- **Northeast (NE)**: The intervention is **more costly** and **more effective**, requiring ICER evaluation to determine if the extra cost is worth the benefit. Drug A‚Äôs **RM 80,000/QALY** falls here, prompting comparison with thresholds like Malaysia‚Äôs **RM 90,000‚Äì120,000/QALY**.
- **Southeast (SE)**: The intervention is **less costly** and **more effective**, making it a **dominant choice** that should be adopted. This is rare but ideal for cost-saving innovations üåü.
- **Southwest (SW)**: The intervention is **less costly** but **less effective**, requiring trade-off evaluation to assess if cost savings justify reduced benefits.
- **Northwest (NW)**: The intervention is **more costly** and **less effective**, typically rejected as it offers no advantage.

In Malaysia, the **cost-effectiveness plane** helps policymakers visualize trade-offs, ensuring decisions align with **budget constraints** and **health priorities**. For Drug A, its position in the **NE quadrant** necessitates careful threshold analysis to justify funding üìà.

### üìä Mini Case: Colorectal Cancer Drug

- **Data**:

|**Option**|**Cost (RM)**|**QALYs Gained**|
|---|---|---|
|Standard Care|20,000|1.5|
|New Drug|60,000|2.0|

- **ICER**: RM 80,000/QALY.
- **Interpretation**:
    - **WTP Threshold (RM 100,000)**: **Cost-effective**.
    - **GDP Threshold (RM 50,000)**: **Borderline/not cost-effective**.
    - **Opportunity Cost (RM 30,000‚Äì40,000)**: **Not cost-effective**.

**Elaboration**: This **mini case** applies **incremental analysis** to a colorectal cancer drug scenario in Malaysia. The **new drug** costs **RM 60,000** and yields **2.0 QALYs**, compared to **standard care** at **RM 20,000** and **1.5 QALYs**. The ICER is calculated as:  
$$\text{ICER} = \frac{60,000 - 20,000}{2.0 - 1.5} = \frac{40,000}{0.5} = \text{RM 80,000 per QALY}$$  
The **interpretation** depends on the threshold:

- **WTP Threshold (RM 100,000)**: The new drug is **cost-effective**, as its ICER is below the MOH/HTA implied threshold, suggesting it‚Äôs a viable investment for Malaysia‚Äôs health system.
- **GDP Threshold (RM 50,000)**: The ICER is **borderline or not cost-effective**, as it exceeds the 1√ó GDP per capita threshold, highlighting the limitations of GDP-based metrics.
- **Opportunity Cost (RM 30,000‚Äì40,000)**: The ICER is **not cost-effective**, as it exceeds the health gains forgone when diverting resources, emphasizing **budget constraints**.

This case underscores the importance of **context-sensitive thresholds** in Malaysia, where **disease severity**, **budget availability**, and **equity** influence whether the new drug is prioritized ü©∫.

---

## üî¨ 8. Sensitivity Analysis

**Sensitivity analysis** is a vital tool in **economic evaluation**, ensuring the **robustness** of results in the face of **uncertainty**. This section explores the **purpose**, **types**, and **applications** of sensitivity analysis, emphasizing its role in strengthening **policy decisions** in Malaysia‚Äôs resource-constrained healthcare system üåç. By testing how changes in parameters like costs or outcomes affect conclusions, sensitivity analysis builds **confidence** in evaluations, guiding **transparent** and **evidence-based** decisions for interventions like cancer treatments or public health programs ü©∫.

### üìñ Why Sensitivity Analysis?

- **Purpose**: Tests **robustness** of results under **uncertainty** in parameters (e.g., costs, utilities, effects).
- **Rationale**: Real-world data are **imperfect**, relying on **assumptions** and **estimates**.
- **Question**: _‚ÄúHow much would our conclusion change if the numbers change?‚Äù_

**Elaboration**: **Sensitivity analysis** addresses the inherent **uncertainty** in economic evaluations, as real-world data, such as drug costs or health outcomes, often rely on **estimates** or **assumptions** that may vary. Its **purpose** is to test whether evaluation results remain **reliable** when key inputs change, ensuring **robust conclusions**. In Malaysia, where healthcare decisions must balance **budget constraints** with **health outcomes**, sensitivity analysis answers the critical question: **How sensitive are our findings to changes in data?** For example, if a new drug‚Äôs price fluctuates or its effectiveness is uncertain, sensitivity analysis reveals whether the intervention remains **cost-effective**, providing policymakers with **confidence** in funding decisions üìä.

### üìã Types of Sensitivity Analysis

The table below outlines the **five types** of sensitivity analysis, their descriptions, and examples in the context of a breast cancer evaluation:

|**Type**|**Description**|**Example (Breast Cancer)**|
|---|---|---|
|**One-Way (Univariate)**|Vary one parameter at a time|Vary Drug A cost from RM 60,000 to RM 40,000|
|**Multi-Way**|Vary multiple parameters simultaneously|Vary drug cost and utility score|
|**Scenario Analysis**|Test plausible real-world scenarios|Assume public vs. private provision costs|
|**Probabilistic (PSA)**|Assign distributions; use Monte Carlo simulation|1,000 simulations of cost, utility values|
|**Threshold Analysis**|Determine value where result changes|At what price is Drug A no longer cost-effective?|

**Elaboration**:

- **One-Way (Univariate) Analysis**: Tests the impact of changing **one parameter** at a time, such as varying the cost of Drug A from **RM 60,000** to **RM 40,000**. This isolates the effect of a single variable, making it simple and useful for identifying **key drivers** in Malaysia‚Äôs cost-sensitive health system üìè.
- **Multi-Way Analysis**: Simultaneously varies **multiple parameters**, like drug cost and utility score, to explore combined effects. This is more realistic, as real-world uncertainties often involve multiple factors, such as fluctuating prices and patient outcomes in Malaysia‚Äôs hospitals üìà.
- **Scenario Analysis**: Examines **plausible real-world scenarios**, such as comparing costs in **public** versus **private healthcare settings**. In Malaysia, this is critical for understanding how delivery context affects **cost-effectiveness**, especially for rural healthcare programs üåç.
- **Probabilistic Sensitivity Analysis (PSA)**: Uses **Monte Carlo simulations** to assign **probability distributions** to parameters, running thousands of scenarios (e.g., 1,000 simulations of costs and utilities). This provides a **range of possible outcomes**, enhancing **confidence** in results for complex interventions like cancer therapies üßÆ.
- **Threshold Analysis**: Identifies the **critical value** at which a result changes, such as the maximum price for Drug A to remain cost-effective. In Malaysia, this helps negotiate drug prices or set **budget limits**, ensuring **policy relevance** üí°.
- **Key Insight**: These methods address different aspects of **uncertainty**, allowing evaluators to tailor analyses to Malaysia‚Äôs healthcare needs, from **budget planning** to **patient-centered care**.

### üìà Example: Breast Cancer Drug A vs. B

- **Base ICER**: RM 80,000/QALY.
- **One-Way Analysis**:
    - If Drug A price drops to **RM 45,000**: ICER = **RM 50,000/QALY** ‚Üí **Cost-effective**.
    - If utility is **0.7** instead of **0.8**: ICER increases ‚Üí **Less cost-effective**.
- **Threshold Analysis**: What‚Äôs the **maximum price** for Drug A to stay below **RM 100,000/QALY**?

**Elaboration**: This example applies **sensitivity analysis** to the comparison of **Drug A** (targeted therapy) versus **Drug B** (standard chemotherapy) for **HER2+ breast cancer**, with a **base ICER** of **RM 80,000/QALY**. **One-way analysis** tests individual parameters:

- Reducing Drug A‚Äôs price to **RM 45,000** lowers the ICER to **RM 50,000/QALY**, making it **cost-effective** under Malaysia‚Äôs **1√ó GDP threshold** (~RM 50,000/QALY) and **MOH/HTA WTP threshold** (RM 90,000‚Äì120,000/QALY).
- Lowering the utility score from **0.8** to **0.7** (reflecting worse quality of life) increases the ICER, making Drug A **less cost-effective**, as fewer QALYs are gained.

**Threshold analysis** determines the **maximum price** at which Drug A‚Äôs ICER remains below **RM 100,000/QALY**, guiding price negotiations in Malaysia‚Äôs health system. This example shows how **sensitivity analysis** identifies **key drivers** (e.g., drug price, utility) and ensures **robust results**, critical for decisions on high-cost interventions like cancer drugs ü©∫.

### üìä Tornado Diagram

- **Purpose**: Visualizes the **impact** of parameter changes on **incremental costs**.
- **Structure**:
    - Each **horizontal bar** shows the range of incremental costs when varying a parameter.
    - **Wider bars** indicate **greater influence**.
    - Parameters ordered from **most to least influential**.

**Elaboration**: A **tornado diagram** is a visual tool that ranks parameters by their **impact** on **incremental costs**, making it easy to identify **key drivers** of cost-effectiveness. Each **horizontal bar** represents the range of cost changes when a parameter, like drug price or utility, is varied. **Wider bars** highlight parameters with **greater influence**, such as Drug A‚Äôs price, while narrower bars indicate less critical factors. In Malaysia, where **budget constraints** are significant, tornado diagrams help policymakers focus on **high-impact variables**, such as negotiating lower drug prices or improving treatment efficacy. This visualization enhances **transparency**, ensuring stakeholders understand which factors drive evaluation outcomes üìâ.

### üåü Purpose of Sensitivity Analysis

- Tests **robustness** of results.
- Identifies **key drivers** of cost-effectiveness.
- Informs **confidence** in policy recommendations.
- Supports **transparent decision-making**.

**Elaboration**: The overarching **purposes** of sensitivity analysis are to:

- **Test Robustness**: Ensures results hold under varying conditions, such as fluctuating costs or uncertain outcomes, critical for Malaysia‚Äôs **variable healthcare data** (e.g., differing costs in public vs. private sectors).
- **Identify Key Drivers**: Pinpoints parameters like drug price or utility that most influence the ICER, guiding **targeted policy actions** like price negotiations or data collection in Malaysia.
- **Inform Confidence**: Provides a **range of outcomes**, increasing trust in recommendations, especially for high-stakes decisions like funding new cancer therapies.
- **Support Transparency**: Clearly shows how uncertainties affect results, ensuring **stakeholder trust** in Malaysia‚Äôs HTA processes.

In Malaysia, sensitivity analysis is essential for **policy-relevant** evaluations, ensuring decisions on interventions like vaccines or cancer treatments are **robust** and **transparent**, maximizing **health impact** within limited budgets üåü.

---

## üßÆ 9. Economic Modeling

**Economic modeling** is a powerful tool in **economic evaluation**, enabling the simulation of **complex** and **long-term** healthcare scenarios when direct data are limited. This section explores the **definition**, **purposes**, **scenarios**, **types**, **components**, **advantages**, and **limitations** of modeling, emphasizing its role in informing **policy decisions** in Malaysia‚Äôs resource-constrained healthcare system üåç. By bridging **data gaps** and projecting **future outcomes**, models support **evidence-based** decisions for interventions like cancer treatments or preventive programs, ensuring **efficiency** and **relevance** in resource allocation ü©∫.

### üìñ Why Use Economic Models?

- **Definition**: _Simplified representations of real-world clinical and economic processes._
- **Purposes**:
    - **Extrapolate** outcomes beyond trial periods.
    - **Simulate** long-term costs and effects.
    - **Compare** interventions without direct head-to-head studies.
    - **Incorporate** uncertainty in decision-making.

**Elaboration**: **Economic models** create **simplified frameworks** to mimic real-world healthcare scenarios, addressing limitations in clinical trial data. Their **purposes** are critical in Malaysia, where **short-term trial data** often fail to capture the **long-term impacts** of interventions like vaccinations or chronic disease treatments. By **extrapolating** outcomes, models project benefits like survival or cost savings over decades. They **simulate** costs and effects for chronic conditions, **compare** interventions lacking direct trials, and **incorporate uncertainty** to ensure robust conclusions. For example, modeling the cost-effectiveness of a new cancer drug in Malaysia helps policymakers evaluate its **long-term value**, guiding decisions that maximize **health outcomes** within **budget constraints** üìä.

### üìã When Modeling is Needed

The table below outlines **scenarios** where economic modeling is essential, along with the **role** it plays:

|**Scenario**|**Modeling Role**|
|---|---|
|Short-term trial data, long-term outcomes|Project outcomes (e.g., survival)|
|Multiple care pathways or disease stages|Capture complexity (e.g., recurrence)|
|Rare diseases or low-event outcomes|Simulate events not captured in trials|
|Budget impact or scenario forecasting|Compare national-scale impact|

**Elaboration**:

- **Short-term Trial Data, Long-term Outcomes**: When trials provide only short-term data (e.g., 2-year follow-up), models project **long-term outcomes** like survival or quality of life, critical for chronic diseases in Malaysia, such as diabetes or cancer üìÖ.
- **Multiple Care Pathways or Disease Stages**: Models capture **complexity**, such as disease progression (e.g., cancer recurrence), ensuring evaluations reflect real-world patient journeys in Malaysia‚Äôs diverse healthcare settings üîÑ.
- **Rare Diseases or Low-Event Outcomes**: For conditions with limited data, like rare cancers, models **simulate events** not observed in trials, enabling evaluations of costly treatments in Malaysia‚Äôs resource-scarce system üß¨.
- **Budget Impact or Scenario Forecasting**: Models assess **national-scale impacts**, such as the cost of rolling out a vaccination program, helping Malaysia‚Äôs Ministry of Health plan budgets and prioritize interventions üí∞.
- **Key Insight**: Modeling is essential when direct data are **incomplete** or **short-term**, ensuring **policy-relevant** evaluations in Malaysia‚Äôs context.

### üìà Breast Cancer Case Example

- **Scenario**: Trial data for Drug A vs. Drug B has a **2-year follow-up**, but:
    - Disease may **recur** after 5 years.
    - **Survival** may extend beyond the trial.
    - **Costs** change post-treatment (e.g., monitoring, recurrence management).
- **Modeling Role**:
    - Estimates **lifetime QALYs**.
    - Projects **long-term costs**.
    - Assesses **cost-effectiveness** over patient lifespan.

**Elaboration**: This case illustrates the need for **modeling** in evaluating **Drug A** (targeted therapy) versus **Drug B** (standard chemotherapy) for **HER2+ breast cancer**. With only **2-year trial data**, key outcomes like **recurrence** after 5 years, **long-term survival**, and **post-treatment costs** (e.g., monitoring or managing recurrence) are missed. A model:

- **Estimates Lifetime QALYs**: Projects **Quality-Adjusted Life Years** over the patient‚Äôs lifespan, capturing **quality of life** and **survival** benefits.
- **Projects Long-term Costs**: Includes costs beyond the trial, such as ongoing monitoring or recurrence treatment, critical for Malaysia‚Äôs budget planning.
- **Assesses Cost-Effectiveness**: Calculates the **Incremental Cost-Effectiveness Ratio (ICER)** over the patient‚Äôs lifespan, ensuring a **comprehensive** evaluation.

In Malaysia, where **chronic diseases** like cancer strain healthcare budgets, modeling ensures **long-term impacts** are considered, supporting decisions on high-cost interventions ü©∫.

### üìä Basic Types of Economic Models

1. **Decision Tree**:
    - **Use**: Short-term, one-time decisions.
    - **Structure**: Branches represent **choices** and **outcomes**.
    - **Example**: Choosing between **Drug A** and **Drug B** for a **6-month adjuvant treatment**.
2. **Markov Model**:
    - **Use**: Chronic conditions or recurrent events.
    - **Structure**: Patients transition between **health states** (e.g., well, recurrence, dead) in **cycles** (e.g., yearly).
    - **Example**: Modeling breast cancer transitions: **Well ‚Üí Local recurrence ‚Üí Metastasis ‚Üí Death**.

**Elaboration**:

- **Decision Tree**: Ideal for **short-term, one-time decisions**, such as choosing between two treatments for a **6-month adjuvant therapy** in breast cancer. The **branches** represent possible **choices** (e.g., Drug A or B) and **outcomes** (e.g., remission, side effects), making it **simple** and **intuitive**. In Malaysia, decision trees are used for acute interventions or short-term evaluations, like surgical procedures, due to their clarity and ease of use üå≥.
- **Markov Model**: Suited for **chronic conditions** or **recurrent events**, like breast cancer, where patients move through **health states** (e.g., well, recurrence, metastasis, death) over **cycles** (e.g., yearly). This captures the **dynamic nature** of diseases, critical for Malaysia‚Äôs evaluations of long-term interventions like cancer therapies or diabetes management üîÑ.
- **Key Insight**: The choice of model depends on the **timeframe** and **complexity** of the intervention, with **decision trees** for short-term clarity and **Markov models** for long-term, complex scenarios in Malaysia‚Äôs healthcare system.

### üîç Key Components of a Markov Model

- **States**: Mutually exclusive (e.g., stable, recurrence, death).
- **Cycles**: Time steps (e.g., yearly).
- **Transition Probabilities**: Likelihood of moving between states.
- **Utilities and Costs**: Assigned to each state per cycle.

**Elaboration**: A **Markov model** is structured around **key components** to simulate patient journeys in chronic conditions:

- **States**: Represent **mutually exclusive health conditions**, such as **stable**, **recurrence**, or **death** in breast cancer. Each patient occupies one state at a time, ensuring clarity in modeling disease progression ü©∫.
- **Cycles**: Divide time into **discrete steps** (e.g., yearly), allowing the model to track changes over time. In Malaysia, yearly cycles are common for chronic disease evaluations to align with healthcare planning üìÖ.
- **Transition Probabilities**: Quantify the **likelihood** of moving between states, such as the probability of progressing from **stable** to **recurrence**. These are derived from clinical data or literature, critical for accuracy in Malaysia‚Äôs context üìä.
- **Utilities and Costs**: Assign **health utilities** (e.g., QALYs) and **costs** to each state per cycle, reflecting quality of life and resource use. For example, the **stable** state may have high QALYs and low costs, while **recurrence** incurs higher costs and lower utilities üí∞.
- **Application**: In Malaysia, Markov models are used to evaluate **chronic diseases** like cancer, ensuring **long-term costs** and **outcomes** are captured for **policy-relevant** decisions.

### üåü Advantages of Modeling

- Captures **long-term outcomes**.
- Incorporates **patient-level variability**.
- Supports **scenario analysis** and **policy planning**.

**Elaboration**: **Economic modeling** offers significant **advantages** in healthcare evaluation:

- **Captures Long-term Outcomes**: Extends beyond trial data to project **survival**, **quality of life**, or **costs** over decades, essential for chronic diseases in Malaysia, such as cancer or diabetes üìà.
- **Incorporates Patient-level Variability**: Accounts for differences in patient outcomes, such as varying response to treatments, ensuring models reflect Malaysia‚Äôs **diverse population** üß¨.
- **Supports Scenario Analysis and Policy Planning**: Allows testing of **what-if scenarios**, like different treatment protocols or budget constraints, aiding Malaysia‚Äôs Ministry of Health in strategic planning for national health programs üåü.
- **Impact**: These advantages make modeling indispensable for **complex** or **long-term** interventions, ensuring evaluations are **comprehensive** and **policy-relevant** in Malaysia‚Äôs healthcare system.

### ‚ö†Ô∏è Limitations

- Relies on **assumptions**.
- **Quality** depends on **input data**.
- **Complex models** may lack **transparency** if not clearly reported.

**Elaboration**: Despite its strengths, **economic modeling** has **limitations**:

- **Relies on Assumptions**: Models depend on **assumptions** about transition probabilities or costs, which may introduce uncertainty if data are limited. In Malaysia, sparse local data can challenge model accuracy üìâ.
- **Quality Depends on Input Data**: The **reliability** of a model hinges on the quality of inputs, such as clinical trial results or cost estimates. Poor data in Malaysia‚Äôs context, especially for rare diseases, can undermine results üîç.
- **Complex Models Lack Transparency**: Highly detailed models may be **difficult to understand** if assumptions or methods are not clearly reported, reducing **stakeholder trust** in Malaysia‚Äôs HTA processes üìë.
- **Mitigation**: Transparent reporting and high-quality data are essential to overcome these limitations, ensuring models are **credible** and **policy-relevant** in Malaysia.

---

## üìö 10. Case Study: HER2+ Breast Cancer

This case study applies the principles of **economic evaluation** to a real-world scenario, comparing **Drug A** (a new targeted therapy) versus **Drug B** (standard chemotherapy) for women with **early-stage HER2+ breast cancer**. This section illustrates how to conduct a **full economic evaluation**, integrating **costing**, **outcome measurement**, **incremental analysis**, and **threshold comparison** to inform **policy decisions** in Malaysia‚Äôs resource-constrained healthcare system üåç. By analyzing **costs**, **outcomes**, and **cost-effectiveness**, this case study highlights the practical application of economic evaluation in prioritizing **high-impact interventions** while addressing **budget constraints** and **equity** concerns ü©∫.

### üìñ Scenario

- **Context**: Comparing **Drug A** (new targeted therapy) vs. **Drug B** (standard chemotherapy) for women with **early-stage HER2+ breast cancer**.
- **Parameters**:
    - **Target Population**: Women with early-stage HER2+ breast cancer.
    - **Perspective**: Health system.
    - **Time Horizon**: 5 years.
    - **Discount Rate**: **3%** (simplified for illustration).

**Elaboration**: This **scenario** focuses on a critical decision for Malaysia‚Äôs healthcare system: whether to adopt **Drug A**, a new targeted therapy, over **Drug B**, the standard chemotherapy, for women with **early-stage HER2+ breast cancer**, a condition with significant health and economic implications. The **target population** is clearly defined to ensure the evaluation is relevant to a specific group, aligning with clinical needs. The **health system perspective** focuses on **direct medical costs** (e.g., drug acquisition, hospital stays), reflecting the priorities of Malaysia‚Äôs Ministry of Health in managing public healthcare budgets. A **5-year time horizon** captures medium-term costs and outcomes, such as survival and quality of life, while the **3% discount rate** adjusts future values to their present worth, aligning with Malaysia‚Äôs Health Technology Assessment (HTA) guidelines. This scenario sets the stage for a **systematic evaluation**, demonstrating how economic tools guide **policy-relevant** decisions in Malaysia üíâ.

### üìä Input Data

The table below presents the **input data** for the economic evaluation of Drug A and Drug B:

|**Intervention**|**Cost (RM)**|**QALYs Gained**|
|---|---|---|
|Drug B (Standard)|20,000|1.5|
|Drug A (New)|60,000|2.0|

**Elaboration**: The **input data** provide the foundation for comparing **Drug A** and **Drug B**. **Costs** are measured in Malaysian Ringgit (RM), with **Drug B** costing **RM 20,000** and **Drug A** costing **RM 60,000**, reflecting the higher expense of targeted therapies. **Quality-Adjusted Life Years (QALYs)** measure health outcomes, with **Drug B** yielding **1.5 QALYs** and **Drug A** yielding **2.0 QALYs**, indicating better survival and quality of life with the new therapy. These data, derived from clinical trials or costing studies, are critical for Malaysia‚Äôs **health system perspective**, ensuring the evaluation reflects **real-world costs** and **health benefits**. Accurate inputs are essential for **credible results**, guiding decisions on whether to fund a costly intervention like Drug A üìä.

### üßÆ Calculations

- **Incremental Cost**:  
    $$\text{Cost}_A - \text{Cost}_B = 60,000 - 20,000 = \text{RM 40,000}$$
- **Incremental QALYs**:  
    $$2.0 - 1.5 = 0.5 \text{ QALYs}$$
- **ICER**:  
    $$\text{ICER} = \frac{40,000}{0.5} = \text{RM 80,000 per QALY}$$

**Elaboration**: The **calculations** apply **incremental analysis** to quantify the **additional cost** and **benefit** of Drug A over Drug B:

- **Incremental Cost**: Subtracting Drug B‚Äôs cost (RM 20,000) from Drug A‚Äôs cost (RM 60,000) yields $$\text{RM 60,000 - 20,000 = RM 40,000}$$, representing the **extra cost** of adopting Drug A.
- **Incremental QALYs**: Subtracting Drug B‚Äôs QALYs (1.5) from Drug A‚Äôs QALYs (2.0) gives $$2.0 - 1.5 = 0.5 \text{ QALYs}$$, indicating the **additional health benefit** of Drug A.
- **Incremental Cost-Effectiveness Ratio (ICER)**: Dividing the incremental cost by the incremental QALYs, $$\text{ICER} = \frac{40,000}{0.5} = \text{RM 80,000 per QALY}$$, shows the **cost per additional QALY** gained by choosing Drug A.

These calculations are critical in Malaysia, where the **ICER** helps policymakers assess whether the **RM 80,000 per QALY** is worth the investment, balancing **health gains** with **budget constraints** üßÆ.

### üìà Interpretation

- **Thresholds**:
    - **WTP (RM 100,000/QALY)**: Drug A is **cost-effective**.
    - **GDP (RM 50,000/QALY)**: Drug A is **not cost-effective**.
    - **Opportunity Cost (RM 30,000‚Äì50,000/QALY)**: Drug A is **not cost-effective**.
- **Decision Factors**:
    - **Budget constraints**.
    - **Disease severity**.
    - **Equity considerations** (e.g., access for low-income patients).

**Elaboration**: The **interpretation** of the ICER (**RM 80,000/QALY**) involves comparing it to **thresholds** that reflect Malaysia‚Äôs willingness to pay for health gains:

- **WTP Threshold (RM 100,000/QALY)**: Drug A‚Äôs ICER of **RM 80,000/QALY** is below the **Ministry of Health/HTA implied willingness-to-pay (WTP)** threshold (RM 90,000‚Äì120,000/QALY), making it **cost-effective**. This suggests Drug A is a viable investment for Malaysia‚Äôs public health system, offering significant health benefits within acceptable cost limits üåü.
- **GDP Threshold (RM 50,000/QALY)**: Based on WHO-CHOICE‚Äôs 1√ó GDP per capita threshold (~RM 50,000/QALY), Drug A is **not cost-effective**, as its ICER exceeds this limit. This highlights the **simplistic nature** of GDP-based thresholds, which may not account for Malaysia‚Äôs specific **budget constraints** or **health priorities**.
- **Opportunity Cost Threshold (RM 30,000‚Äì50,000/QALY)**: Reflecting the **health gains forgone** when diverting resources, this threshold deems Drug A **not cost-effective**, as its ICER exceeds the range. This is critical in Malaysia, where **scarce resources** require prioritizing interventions with lower opportunity costs üìâ.

**Decision Factors** influence the final recommendation:

- **Budget Constraints**: Malaysia‚Äôs limited healthcare budget may restrict funding for costly interventions like Drug A, despite its cost-effectiveness under the WTP threshold.
- **Disease Severity**: The life-threatening nature of HER2+ breast cancer may justify higher costs, as improved survival and quality of life are critical.
- **Equity Considerations**: Ensuring **access for low-income patients** is vital in Malaysia, where out-of-pocket costs can exacerbate **financial toxicity**. A **health system perspective** may overlook these, but **equity** could tip the decision toward funding Drug A if it addresses unmet needs.

This interpretation underscores the need for **context-sensitive analysis** in Malaysia, balancing **cost-effectiveness**, **health priorities**, and **equity** to guide **policy decisions** üìä.

---

## üö´ 11. Common Mistakes in Economic Evaluation

**Economic evaluations** are essential for guiding **resource allocation** in healthcare, but common mistakes can compromise their **credibility** and **policy relevance**. This section outlines **seven key errors** to avoid, emphasizing the need for **methodological clarity** and **transparency** in Malaysia‚Äôs resource-constrained healthcare system üåç. By understanding these pitfalls, public health professionals can ensure evaluations are **robust**, **transparent**, and aligned with **policy priorities**, supporting decisions on interventions like cancer treatments or public health programs ü©∫.

### üìñ Overview

Robust economic evaluations require **methodological clarity** and **transparency**. Common errors can undermine **credibility** and **policy relevance**.

**Elaboration**: A **robust economic evaluation** is one that is **systematic**, **transparent**, and **relevant** to decision-makers, providing a reliable basis for allocating Malaysia‚Äôs limited healthcare resources. Errors in methodology or reporting can lead to **misleading conclusions**, reducing trust in evaluations and potentially misguiding **policy decisions**. For example, an evaluation of a new vaccine program in Malaysia must be clear and accurate to justify funding over other priorities. This section highlights **seven common mistakes**, offering insights and examples to help students avoid them, ensuring evaluations are **credible** and **impactful** üìã.

### üìã Seven Common Mistakes

The table below summarizes the **seven common mistakes** in economic evaluation, their importance, pitfalls, and examples, providing a quick reference for avoiding errors:

|**Mistake**|**Why It Matters**|**Pitfall**|**Example**|
|---|---|---|---|
|Inappropriate/Unstated Perspective|Determines **cost** and **outcome** inclusion|Using a **narrow perspective** when **societal impact** is relevant|Ignoring **OOP costs** in a cancer care study for low-income populations|
|Incorrect/Inconsistent Costing|Accurate costing is the **foundation**|Using **outdated prices**, not adjusting for **inflation**, or mixing **price sources**|Using **private hospital rates** in a **public sector** evaluation|
|Inadequate Time Horizon|Short horizons miss **long-term benefits** or **harms**|Limiting to **trial duration** for chronic conditions|**1-year horizon** for breast cancer, missing **10-year recurrence risk**|
|No Discounting|**Time preference** must be accounted for|Ignoring discounting for horizons **exceeding 1 year**|Reporting **lifetime QALYs** without a **discount rate**|
|Missing/Weak Sensitivity Analysis|**Uncertainty** requires robust testing|No analysis or testing **trivial variables**|Not testing **utility score variations** for high-impact side effects|
|No Incremental Comparison/ICER Misuse|**ICER** is core to decision-making|Reporting **total cost** and **QALYs** without comparing alternatives|Stating ‚ÄúDrug A yields 2 QALYs at RM 70,000‚Äù without comparing Drug B|
|Lack of Transparency/Reproducibility|Policymakers need clear **assumptions**|Unclear reporting of **data sources**, **model assumptions**, or **methods**|Using a **Markov model** without showing **transition probabilities** or **utility weights**|

#### 1. Inappropriate or Unstated Perspective

- **Why It Matters**: Perspective determines **cost** and **outcome** inclusion.
- **Pitfall**: Using a **narrow perspective** (e.g., provider) when **societal impact** is relevant.
- **Example**: Ignoring **OOP costs** in a cancer care study for low-income populations.

**Elaboration**: The **perspective** defines which **costs** (e.g., drugs, travel) and **outcomes** (e.g., survival, productivity) are included, directly shaping the evaluation‚Äôs scope. Choosing an **inappropriate perspective**, such as a **provider perspective** when **societal impacts** like patient out-of-pocket (OOP) costs are critical, can skew results. For instance, ignoring **OOP costs** in a cancer care study for Malaysia‚Äôs low-income populations overlooks **financial toxicity**, undermining **equity considerations**. Similarly, failing to state the perspective reduces **transparency**, confusing policymakers. In Malaysia, where **equity** and **access** are priorities, clearly defining and justifying the perspective ensures evaluations align with **stakeholder needs** üëÅÔ∏è.

#### 2. Incorrect or Inconsistent Costing

- **Why It Matters**: Accurate costing is the **foundation** of evaluation.
- **Pitfall**: Using **outdated prices**, not adjusting for **inflation**, or mixing **price sources**.
- **Example**: Using **private hospital rates** in a **public sector** evaluation.

**Elaboration**: **Accurate costing** is essential for credible evaluations, as it reflects the **true resource use** of interventions. Errors like using **outdated prices**, failing to adjust for **inflation**, or mixing **price sources** (e.g., private vs. public rates) can lead to **inconsistent** or **misleading** cost estimates. For example, applying **private hospital rates** in a **public sector** evaluation in Malaysia overstates costs, as public hospitals use standardized tariffs. This can distort the **Incremental Cost-Effectiveness Ratio (ICER)**, leading to poor policy decisions. In Malaysia‚Äôs cost-sensitive health system, consistent use of **local data** (e.g., Ministry of Health fee schedules) ensures evaluations are **reliable** and **policy-relevant** üí∞.

#### 3. Inadequate Time Horizon

- **Why It Matters**: Short horizons miss **long-term benefits** or **harms**.
- **Pitfall**: Limiting analysis to **trial duration** for chronic conditions.
- **Example**: **1-year horizon** for breast cancer, missing **10-year recurrence risk**.

**Elaboration**: The **time horizon** determines how far into the future **costs** and **outcomes** are tracked, and an **inadequate horizon** can miss critical impacts. For chronic conditions like breast cancer, limiting the analysis to a **1-year horizon** (e.g., trial duration) captures immediate costs but misses **long-term benefits** like reduced recurrence or **harms** like late side effects. In Malaysia, where **chronic diseases** strain healthcare budgets, a **lifetime horizon** is often needed to fully assess interventions like cancer therapies. An inadequate horizon biases against **long-term interventions**, such as preventive programs, reducing their perceived value and undermining **policy decisions** ‚è∞.

#### 4. No Discounting of Future Costs/Benefits

- **Why It Matters**: **Time preference** must be accounted for in long-term evaluations.
- **Pitfall**: Ignoring discounting for horizons **exceeding 1 year**.
- **Example**: Reporting **lifetime QALYs** without a **discount rate**.

**Elaboration**: **Discounting** adjusts **future costs** and **outcomes** to their **present value**, reflecting **time preference** (valuing benefits now over later). Failing to apply discounting for horizons **exceeding 1 year**, as required in Malaysia‚Äôs HTA guidelines (typically **3%**), overstates future benefits like **lifetime QALYs**. For example, reporting QALYs for a cancer treatment without a **discount rate** inflates its value, leading to **misinformed decisions**. In Malaysia, where **long-term interventions** like vaccinations are common, discounting ensures **fair comparisons** between immediate and future benefits, aligning with **budget constraints** üï∞Ô∏è.

#### 5. Missing or Weak Sensitivity Analysis

- **Why It Matters**: **Uncertainty** requires robust testing.
- **Pitfall**: No analysis or testing **trivial variables**.
- **Example**: Not testing **utility score variations** for high-impact side effects.

**Elaboration**: **Sensitivity analysis** tests the **robustness** of results under **uncertainty** in parameters like costs or utilities. Missing or conducting **weak sensitivity analysis**‚Äîe.g., testing only **trivial variables**‚Äîfails to address critical uncertainties, reducing **confidence** in findings. For instance, not testing **utility score variations** for side effects in a cancer drug evaluation ignores their impact on **quality of life**, potentially misrepresenting **cost-effectiveness**. In Malaysia, where data uncertainties (e.g., fluctuating drug prices) are common, robust sensitivity analysis ensures **reliable recommendations**, supporting **transparent decision-making** üî¨.

#### 6. No Incremental Comparison or ICER Misuse

- **Why It Matters**: **ICER** is core to decision-making.
- **Pitfall**: Reporting **total cost** and **QALYs** without comparing alternatives.
- **Example**: Stating ‚ÄúDrug A yields 2 QALYs at RM 70,000‚Äù without comparing Drug B.

**Elaboration**: The **Incremental Cost-Effectiveness Ratio (ICER)** compares the **additional cost** and **benefit** of one intervention over another, making it central to **decision-making**. Failing to perform **incremental comparison** or misusing ICER by reporting only **total costs** and **QALYs** (e.g., ‚ÄúDrug A yields 2 QALYs at RM 70,000‚Äù) without comparing to Drug B obscures **relative value**. In Malaysia, where policymakers need to choose between competing interventions, ICER ensures **cost-effectiveness** is assessed relative to alternatives, guiding **resource allocation** for interventions like new drugs üìà.

#### 7. Lack of Transparency or Reproducibility

- **Why It Matters**: Policymakers need clear **assumptions**.
- **Pitfall**: Unclear reporting of **data sources**, **model assumptions**, or **methods**.
- **Example**: Using a **Markov model** without showing **transition probabilities** or **utility weights**.

**Elaboration**: **Transparency** and **reproducibility** are essential for building **stakeholder trust**, as policymakers in Malaysia rely on clear **assumptions** to validate evaluations. Unclear reporting of **data sources**, **model assumptions**, or **methods**‚Äîsuch as using a **Markov model** without documenting **transition probabilities** or **utility weights**‚Äîreduces **credibility** and makes results difficult to verify. For example, a cancer treatment evaluation in Malaysia must clearly state data sources (e.g., hospital records) and model details to ensure **reproducibility**. Transparent reporting aligns evaluations with **policy needs**, fostering trust in **HTA processes** üìë.

---

## ‚úÖ 12. Conclusion

The **conclusion** of **Economic Evaluation II** synthesizes the key lessons from the lecture, emphasizing the importance of **robust**, **transparent**, and **policy-relevant** economic evaluations in Malaysia‚Äôs resource-constrained healthcare system üåç. This section recaps the **essential components** of a well-conducted evaluation and reflects on their role in navigating **scarcity** to achieve **efficiency**, **equity**, and **sustainability**. By mastering these methodologies, public health professionals can drive **evidence-based decisions**, ensuring **better health outcomes** for Malaysia‚Äôs diverse population ü©∫.

### üìù Key Takeaways

- **Conducting a robust economic evaluation** requires more than calculations‚Äîit demands:
    - **Clear definition** of the problem and perspective.
    - **Accurate costing** and **meaningful outcome measurement**.
    - Use of **ICER** and **modeling** for long-term decisions.
    - **Testing uncertainty** through sensitivity analysis.
- **Foundation**: A well-conducted evaluation is **structured**, **transparent**, and **policy-relevant**, systematically comparing **cost** and **value** to support **wise decisions**.

**Elaboration**: A **robust economic evaluation** goes beyond simple number-crunching; it requires a **systematic approach** to ensure **credibility** and **relevance**. The **key components** include:

- **Clear Definition of the Problem and Perspective**: Defining the health issue (e.g., adopting a new cancer drug) and choosing the appropriate **perspective** (e.g., health system or societal) ensures the evaluation addresses **specific policy questions** and includes relevant **costs** and **outcomes**. In Malaysia, where **resource allocation** is critical, clarity in problem definition aligns evaluations with **national health priorities** üìã.
- **Accurate Costing and Meaningful Outcome Measurement**: Precise **costing** (e.g., using local hospital tariffs) and **outcome measurement** (e.g., QALYs for quality of life) provide a **reliable foundation**. In Malaysia, accurate data from sources like the Ministry of Health ensures evaluations reflect **real-world conditions**, such as public sector costs or patient outcomes üí∞üìà.
- **Use of ICER and Modeling**: The **Incremental Cost-Effectiveness Ratio (ICER)**, calculated as $$\text{ICER} = \frac{\text{Cost}_{\text{New}} - \text{Cost}_{\text{Comparator}}}{\text{Effect}_{\text{New}} - \text{Effect}_{\text{Comparator}}}$$, quantifies **cost-effectiveness**, while **modeling** (e.g., Markov models) projects **long-term outcomes** for chronic conditions. These tools are vital in Malaysia for evaluating interventions like vaccinations, where benefits unfold over decades üßÆ.
- **Testing Uncertainty through Sensitivity Analysis**: **Sensitivity analysis** tests the **robustness** of results under uncertainty, identifying **key drivers** like drug prices. In Malaysia‚Äôs context, where data may vary (e.g., costs in rural vs. urban settings), this ensures **confidence** in policy recommendations üî¨.
- **Foundation**: A well-conducted evaluation is **structured** (following the 10 steps), **transparent** (clearly reporting assumptions), and **policy-relevant** (aligned with Malaysia‚Äôs health goals). By systematically comparing **cost** and **value**, evaluations support **wise decisions**, such as prioritizing cost-effective treatments or equitable access programs üåü.

### üåü Final Reflection

Economic evaluations are essential for navigating **scarcity** in healthcare, ensuring **efficiency**, **equity**, and **sustainability**. By mastering these methodologies, public health professionals can guide Malaysia‚Äôs health system toward **better outcomes** for all üá≤üáæ.

**Elaboration**: **Economic evaluations** are indispensable in Malaysia, where **scarcity** of healthcare resources demands **strategic allocation** to maximize **health impact**. By ensuring **efficiency**, evaluations identify interventions that deliver the **greatest health benefits** per ringgit spent, such as cost-effective cancer therapies. **Equity** ensures access for underserved populations, like rural communities or low-income patients, addressing Malaysia‚Äôs commitment to **universal health coverage**. **Sustainability** ensures long-term viability, balancing immediate costs with future benefits, such as preventive programs like HPV vaccination. By mastering these methodologies, public health professionals can steer Malaysia‚Äôs health system toward **better outcomes**, improving **survival**, **quality of life**, and **access to care** across diverse populations. This empowers professionals to make **evidence-based**, **policy-relevant** decisions, transforming Malaysia‚Äôs healthcare landscape for the benefit of all üá≤üáæ.

### üìù Summary Table: Key Elements of Robust Economic Evaluation

The table below summarizes the **essential components** of a robust economic evaluation, highlighting their role in Malaysia‚Äôs healthcare system:

|**Component**|**Description**|**Relevance to Malaysia**|
|---|---|---|
|**Clear Definition**|Define the problem and perspective|Aligns with policy priorities, e.g., cancer care or rural access üìã|
|**Accurate Costing**|Use reliable, context-specific cost data|Reflects public sector tariffs, ensuring budget relevance üí∞|
|**Meaningful Outcomes**|Measure outcomes like QALYs|Captures patient-centered benefits, vital for equity üåü|
|**ICER**|Quantify cost per health benefit|Guides cost-effectiveness decisions within budget constraints üßÆ|
|**Modeling**|Project long-term outcomes|Essential for chronic diseases and preventive programs üìä|
|**Sensitivity Analysis**|Test uncertainty in parameters|Builds confidence in recommendations despite data variability üî¨|
|**Structured & Transparent**|Follow systematic steps, report clearly|Ensures credibility and stakeholder trust in HTA processes üìë|

---

## üìù Self-Assessment Questions for HE 10 - Economic Evaluation II

The following questions are designed to help students assess their understanding of **HE 10 - Economic Evaluation II**, delivered on **May 30, 2025**, as part of the **MQB7014: Health Economics** module. These questions cover **conceptual understanding**, **quantitative skills**, **application**, **critical analysis**, **synthesis**, and **policy recommendations**, with a focus on Malaysia‚Äôs healthcare context and global applications üåç.

### üìö Short Answer Questions

These questions test **conceptual understanding** of key terminologies and principles from the lecture.

1. Define **economic evaluation** and explain its **core idea** in the context of healthcare resource allocation.
2. What is the difference between **micro-costing** and **gross-costing**, and when should each be used in Malaysia‚Äôs healthcare system?
3. Explain the concept of **time preference** and its relevance to **discounting** in economic evaluations.
4. Describe the **cost-effectiveness plane** and identify the four quadrants used to evaluate interventions.
5. What is a **Quality-Adjusted Life Year (QALY)**, and why is it important in **Cost-Utility Analysis (CUA)**?
6. Differentiate between a **decision tree** and a **Markov model** in economic modeling, providing an example of when each is appropriate.
7. Why is **sensitivity analysis** critical in economic evaluations, and what question does it aim to answer?
8. List three **common mistakes** in economic evaluation and explain why they undermine **policy relevance**.
9. What is meant by **opportunity cost** in the context of healthcare resource allocation in Malaysia?
10. How does the choice of **perspective** (e.g., societal, health system) affect the outcomes of an economic evaluation?

### üßÆ Calculation-based Questions

These questions test **quantitative skills** by applying the **Incremental Cost-Effectiveness Ratio (ICER)** and **discounting** concepts.

1. A new diabetes drug costs RM 50,000 and yields 3.0 QALYs, while the standard drug costs RM 20,000 and yields 2.5 QALYs. Calculate the **ICER** and interpret whether it is **cost-effective** using Malaysia‚Äôs **WTP threshold** of RM 100,000/QALY. Show your calculations:  
    $$\text{ICER} = \frac{\text{Cost}_{\text{New}} - \text{Cost}_{\text{Comparator}}}{\text{Effect}_{\text{New}} - \text{Effect}_{\text{Comparator}}}$$
    
2. A vaccination program costs RM 10 million and prevents 1,000 cases of disease over 5 years. The comparator (no vaccination) costs RM 2 million and prevents 200 cases. Calculate the **ICER** in terms of cost per case prevented. Is it **cost-effective** if the threshold is RM 15,000 per case prevented?
    
3. A cancer treatment yields 1.2 QALYs over 3 years without discounting. Using a **3% discount rate**, calculate the **present value** of QALYs. Assume continuous discounting with the formula:  
    $$\text{PV} = \text{Value} \times e^{-rt}$$  
    where ( r = 0.03 ), ( t = 3 ), and ( $e \approx 2.71828$ ).
    
4. A new therapy costs RM 80,000 and yields 4.0 QALYs, while the standard therapy costs RM 30,000 and yields 3.0 QALYs. Calculate the **ICER**. If a **sensitivity analysis** reduces the cost of the new therapy to RM 60,000, recalculate the ICER and compare it to Malaysia‚Äôs **GDP threshold** of RM 50,000/QALY.
    
5. A preventive intervention yields RM 100,000 in productivity gains over 10 years. Using a **3% discount rate**, calculate the **present value** of these gains. Use the formula:  
    $$\text{PV} = \frac{\text{FV}}{(1 + r)^t}$$  
    where ($\text{FV} = 100,000$), ( r = 0.03 ), and ( t = 10 ).
    

### üìù Short-Essay Questions

These questions require students to apply concepts to **practical scenarios**, demonstrating **conceptual understanding** and **problem-solving skills**.

1. Explain how the choice of **perspective** (e.g., societal vs. health system) affects the evaluation of a new malaria treatment in Malaysia. Provide an example of costs included in each perspective and discuss how this impacts **policy decisions** for rural communities üåç.
    
2. Describe the role of **sensitivity analysis** in ensuring **robust economic evaluations**. Using the breast cancer case (Drug A vs. Drug B), illustrate how **one-way** and **probabilistic sensitivity analysis** can influence Malaysia‚Äôs decision to fund Drug A üî¨.
    
3. Discuss why a **long-term time horizon** is critical for evaluating preventive interventions like HPV vaccination in Malaysia. Explain the risks of using a **short horizon** and how **discounting** affects the results üï∞Ô∏è.
    
4. Compare **decision trees** and **Markov models** in economic modeling, using examples from Malaysia‚Äôs healthcare system (e.g., diabetes management). Discuss when each is appropriate and how they address **data gaps** üìä.
    
5. Explain the importance of **transparency** in economic evaluations, referencing the common mistake of **lack of transparency**. Provide an example of how unclear reporting could affect Malaysia‚Äôs HTA process for a new cancer drug üìë.
    

### ü©∫ Structured Case Study Questions

These questions require **critical analysis** and **policy recommendations** for complex scenarios, with **sub-questions** to structure responses.

**Case Study: Mobile Dental Clinic in Rural Malaysia**  
The Ministry of Health is considering a **mobile dental clinic** versus a **fixed subsidy scheme** to improve dental care access in rural areas. The clinic costs RM 5 million over 5 years, yielding 2,000 QALYs, while the subsidy costs RM 2 million and yields 1,500 QALYs. Use a **health system perspective** and **3% discount rate**.

1. **Sub-Questions**:
    - **Calculate the ICER**: Using the formula $$\text{ICER} = \frac{\Delta \text{Cost}}{\Delta \text{Effect}}$$, compute the ICER for the mobile clinic versus the subsidy scheme üßÆ.
    - **Interpret Cost-Effectiveness**: Compare the ICER to Malaysia‚Äôs **WTP threshold** (RM 100,000/QALY) and **GDP threshold** (RM 50,000/QALY). Is the mobile clinic cost-effective? üìà
    - **Sensitivity Analysis**: Discuss how varying **staff costs** or **fuel prices** could affect the ICER. Propose one **one-way** and one **probabilistic** sensitivity analysis üî¨.
    - **Policy Recommendation**: Based on the ICER and **equity considerations** (e.g., rural access), recommend whether Malaysia should adopt the mobile clinic. Justify with **decision factors** like **budget constraints** ü¶∑.

**Case Study: New Tuberculosis (TB) Treatment**  
A new TB drug costs RM 30,000 and yields 3.5 QALYs, while the standard treatment costs RM 10,000 and yields 2.8 QALYs. Use a **societal perspective** and **10-year horizon** with a **3% discount rate**.

2. **Sub-Questions**:
    - **Identify Costs and Outcomes**: List relevant costs (e.g., **direct medical**, **indirect**) and outcomes for the societal perspective üìã.
    - **Calculate the ICER**: Compute the ICER and apply **discounting** to QALYs using $$\text{PV} = \frac{\text{FV}}{(1 + r)^t}$$
    - **Interpret Results**: Compare the ICER to Malaysia‚Äôs **opportunity cost threshold** (RM 30,000‚Äì50,000/QALY). Discuss the impact of **disease severity** on the decision üìà.
    - **Policy Recommendation**: Recommend whether to fund the new TB drug, considering **equity** (e.g., low-income patients) and **budget constraints** üåç.

### üìë Open-Ended Long Essay Questions

These questions require **in-depth analysis** of complex healthcare challenges, encouraging **critical thinking**, **synthesis**, and **policy recommendations** with **Malaysia-specific** and **global applications**.

1. Discuss the role of **economic evaluation** in addressing **scarcity** in Malaysia‚Äôs healthcare system. Using the **HER2+ breast cancer case**, analyze how **ICER**, **sensitivity analysis**, and **modeling** guide funding decisions. Propose strategies to balance **efficiency**, **equity**, and **sustainability** in Malaysia, and compare these to global practices (e.g., UK‚Äôs NICE) üåçü©∫.
    
2. Evaluate the importance of **perspective** in economic evaluations, focusing on **societal** versus **health system** perspectives. Using the **mobile dental clinic case**, discuss how perspective impacts **cost-effectiveness** and **equity** in rural Malaysia. Suggest how Malaysia can integrate **global best practices** (e.g., WHO-CHOICE) to enhance **policy relevance** ‚öñÔ∏èüìä.
    
3. Analyze the challenges of evaluating **preventive interventions** like HPV vaccination in Malaysia, focusing on **time horizon**, **discounting**, and **uncertainty**. Propose a **Markov model** framework to assess long-term outcomes, and discuss how **sensitivity analysis** can address data limitations. Compare Malaysia‚Äôs approach to global standards (e.g., WHO guidelines) üíâüî¨.
    
4. Critically assess the **common mistakes** in economic evaluation and their impact on **policy decisions** in Malaysia. Using a hypothetical new diabetes drug, illustrate how errors like **inadequate time horizon** or **ICER misuse** could mislead funding decisions. Recommend strategies to ensure **transparency** and **robustness**, drawing on global HTA frameworks üìëüåü.
    

---
